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ABSTRACT 
Obesity causes several health problems, including insulin resistance, Type 2 diabetes, heart 
diseases, disrupted energy metabolism and low-grade inflammation. Being obese increases 
the risk of getting metabolic syndrome.  
A high intake of certain carbohydrates is known to cause rapid rise in blood glucose, which 
increases insulin secretion and over time causes insulin resistance and hyperglycemia. A high 
consumption of sucrose and glucose is considered harmful beyond being a source of energy 
due to their ability to disturb energy metabolism. On the other hand, fish oil, enriched in the 
polyunsaturated fatty acids eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid 
(DHA; 22:6n-3), can protect against the development of obesity, improve insulin sensitivity, 
reduce visceral fat, reduce inflammation of adipose tissue and reduce metabolic efficiency. 
This study seeks to elucidate the potential ameliorating effect of fish oil on the negative 
effects of high carbohydrate consumption.  
Two trials using C57BL/6J mice were performed simultaneously. One of the trials 
investigated the effect of different sugars, namely the disaccharide sucrose and the 
monosaccharides glucose and fructose. Three groups of mice received either high sucrose, 
high glucose or high fructose diet in combination with fish oil. The other trial investigated the 
effects of different starches, namely amylose and amylopectin, in combination with fish oil. 
One group was given amylose (low GI carbohydrate) and the other group was given 
amylopectin (high GI). All the five experimental diets were high in fat, primarily fish oil. All 
groups, except the chow diet controlgroup, were pair-fed. Feed intake was recorded daily and 
body weight was recorded twice a week. After 9 weeks of experimental feeding, the mice 
were terminated and tissues and blood samples were collected. Gene expression analysis of 
the different tissues was performed by quantitative real-time PCR. Blood plasma was 
analyzed for plasma parameters. Paraffin-embedded, stained sections of adipose tissue were 
examined in a microscope. Fatty acid compositions were determined in liver and muscle.  
The results show that fish oil protected the mice given fructose and low GI carbohydrates 
from developing obesity. These groups had smaller adipose tissues and less inflammation 
compared to other groups. The primary cause of this seems to be that the PUFAs in fish oil 
decrease hepatic and adipose tissue lipogenesis. 
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1. INTRODUCTION 
1.1 OBESITY 
Overweight and obesity are defined as the excessive accumulation of fat to the point where it 
presents a risk to the individual’s health (WHO 2011). Obesity can be measured by the body 
mass index (BMI). An individual’s BMI is calculated by his or her weight in kilograms, 
divided by the square of his or her height in meters: 
BMI  
           
                   
 
The optimum BMI range is between 18.5 and 25. A person with BMI equal to or above 25 is 
considered as overweight, whereas a person with BMI of 30 or more is considered as obese. It 
is natural for a woman to have lower BMI compared to a man of same height, due to less 
muscle mass in the average female body. The optimum BMI range of 18.5 to 25 does not 
apply to lean people of heavy muscular build, children or elderly. Also, due to the nature of 
the BMI formula, it has limited use for people who are relatively short or tall of stature. For 
people of short stature (150≤ cm for women and 160 cm≤ for men), obesity-related problems 
increase when the BMI exceeds 23 (Lara-Esqueda et al 2004). Inversely, tall people can have 
higher BMI without being overweight. There are several other ways of measuring obesity, e.g. 
the waist-hip ratio or body fat percentage.  
Obesity is caused by a positive energy balance, which is energy intake that exceeds energy 
expenditure. In some countries the average energy intake is decreasing, but the prevalence of 
obesity is still increasing (Elmadfa et al 2009). This may primarily be caused by a more 
sedentary lifestyle which decreases energy expenditure, but it is our hypothesis that the 
development of obesity may be influenced by the diet.  
Obesity and overweight the rank among the highest risk factors for premature death. Every 
year, at least 2.8 million adults die prematurely as a result of being overweight or obese 
(WHO 2011). Obesity increases the risk of chronic diseases like diabetes Type 2, 
cardiovascular diseases, hypertension, cancer, stroke, gallstone formation, musculoskeletal 
disorders, sleep apnea and back pain (Helsedirektoratet 2008). The risk of developing these 
diseases increase with increasing BMI (WHO 2011). In addition to being a problem for the 
individual’s health, welfare and life expectancy, it is also a major expenditure for the society 
in the form of increased health care costs and decreased tax revenues (Finkelstein et al 2003). 
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In 2008, 1.5 billion adults at the age of 20 and older were overweight. 500 millions of these 
were obese. In 2010, nearly 43 million children under the age of 5 were overweight. Obesity 
was once considered a problem in developed countries, but in recent years it has been on the 
rise in developing countries as well (WHO 2011). In developing countries, poverty can cause 
both undernutrition and overnutrition, even within the same household, partly due to the high 
cost of healthy foods. The prevalence of obesity worldwide is higher in cities compared to 
rural areas and higher in female population compared to males (Usfar et al 2010). In EU 
countries, obesity is more widespread among men compared to females. Norway has one of 
the lowest prevalence of obesity in Europe (Elmadfa et al 2009), even though 13-22% of 40-
45 year olds are reported to be obese (FHI 2011).   
Childhood obesity is associated with a higher risk of obesity and obesity-related diseases in 
adulthood. It is also difficult to maintain long lasting weigh reduction for people who have 
previously suffered from overweight or obesity. Prevention of obesity development, 
especially in children, is therefore of critical importance. Among the advice given from World 
Health Organization (WHO) to prevent obesity are limiting the energy intake from total fats 
and sugar, increasing consumption of fruit, vegetables, whole grains and nuts, and engaging in 
regular physical activity (WHO 2011). These vague advices are supported by the WHO 
“2008-2013 Action Plan for the Global Strategy for the Prevention and Control of 
Noncommunicable Diseases” (NCDs). This Action Plan mentions obesity only once and 
states that one should promote interventions aimed to reduce unhealthy diets in e.g. schools, 
workplaces, households and local communities. The plan was developed to “help the millions 
who are already affected cope with these lifelong illnesses and prevent secondary 
complications. (...) The action plan provides a roadmap to establish and strengthen initiatives 
for the surveillance, prevention and management of NCDs.” (WHO 2008). Good intentions 
seem to be of abundance in the area of politics, whereas measurable results are scarce.  
 
1.2 MACRONUTRIENTS IN RELATION TO OBESITY 
The three macronutrient classes are carbohydrates, fats and proteins. Carbohydrates include 
starches, sugars and fiber. Fat is broadly divided into saturated, monounsaturated and 
polyunsaturated fats, all of which have different effect on human health in addition to being a 
source of energy. Examples of omega-3 polyunsaturated fatty acids include alpha-linolenic 
acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), where EPA and 
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DHA are found in marine foods. EPA and DHA are essential to human health, but ingested 
ALA can to some extent be converted into EPA and DHA. Proteins consist of 20 different 
amino acids, where 8 are essential to human health. 
Dietary carbohydrates  
Dietary carbohydrates account for 45-70% of energy intake in developed countries. 
Carbohydrates are divided into starches, sugars and fiber. Sugars refer to monosaccharides, 
like glucose and fructose, and disaccharides, like sucrose. Sucrose consists of one glucose and 
one fructose molecule (Fig 1.1). Sucrose is broken down into glucose and fructose upon 
digestion (Schaefer et al 2009). 
    
Figure 1.1: Glucose, fructose and sucrose molecules. (Adapted from http://drpinna.com/fructose-is-a-
cause-of-cancer-18119/glucose-fructose-and-sucrose-3) 
Sugar is added to food because of its sweet taste and inexpensive cost. Since the advent of 
modern food-processing methods, sugar consumption has risen steadily. Whereas sucrose is 
the main sweetener in most countries, high fructose corn syrup (HFCS) made from corn starch 
is an even cheaper, widely used sweetener in USA. HFCS consists of approximately 45% 
glucose and 55% fructose and has a slightly sweeter taste compared to sucrose (Bray et al 
2004). 
The body uses glucose as its primary source of energy and transports it around by the blood 
stream. The brain and red blood cells are dependent on glucose and ketones as fuel, therefore 
blood glucose levels are tightly regulated. Glucose is broken down to carbon dioxide and 
water through the tricarboxylic acid cycle (TCA). Glucose is also stored as glycogen in liver 
and muscles, as a source of rapidly available energy. Excess glucose ingested is converted to 
fatty acids for storage in adipose tissues (Schaefer et al 2009). 
Blood glucose levels are tightly regulated, primarily by the hormone insulin. Insulin is 
released by β-cells in the pancreas as a response to postprandial high glucose levels. It has 
several effects, the most important being that it binds to target organ cells and promote 
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glucose transport into the cell. Thus, it reduces blood glucose to normal levels. Insulin 
resistance is the state where the cells no longer respond to normal levels of insulin and blood 
glucose levels remain high. This increases the insulin production in the pancreas, putting 
strain on the β-cells. Insulin resistance is an early sign of Type 2 diabetes (Petersen and 
Shulman 2002). Fructose does not raise blood glucose or insulin levels. These may seem 
beneficial, but fructose is converted into glucose or fat in the liver. High fructose diets are a 
common way of inducing insulin resistance, obesity and metabolic syndrome in rat models 
(Hwang et al 1987, Tran et al 2009) . High fructose intake has been associated with lipid 
abnormalities, visceral adiposity and nonalcoholic liver steatosis (Schaefer et al 2009, Tappy 
and Le 2010).  
Starches are polymers of glucose molecules which are either linear or branched. Amylose and 
amylopectin are both starches found in plants (Fig 1.2). Amylose molecules only have α-1,4 
linkages between the glucose molecules, making them linear. Amylopectin molecules are 
large, made up by over 10 000 glucose molecules, and have α-1,6 linkages between the 
glucose molecules, in addition to the α-1,4 linkages. This gives amylopectin a branched, tree-
like structure. Total ingested starch usually consists of 20-30% amylose and 70-80% 
amylopectin (Cummings and Englyst 1995). 
          
Figure 1.2: Amylose (left) and amylopectin (right). (Adapted from 
http://www.cbu.edu/~seisen/OrganicChemistry.htm) 
Before absorption from the gut into the body, the starches must be cleaved into 
monosaccharides. The digestion enzymes in the gut can only cleave glucose molecules off the 
end of the polysaccharides. Since the branched amylopectin molecule have many ends for the 
digestion enzymes to work on, glucose molecules are rapidly released from amylopectin 
compared to amylose (Cummings and Englyst 1995). 
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Glycemic index 
The term glycemic index (GI) refers to how a food, meal or diet can raise blood glucose after 
consumption. The GI of a food is defined as the two-hour area under the blood glucose 
response curve (AUC) after eating a portion of that food which contains 50 g of 
carbohydrates. This number is then divided by the AUC number of a standard, which is 50 g 
glucose or white bread consumed by the same person that same day, and then multiplied by 
100 (van Baak and Astrup 2009). The GI values of different foods have been published 
(Atkinson et al 2008), but it is reported that the same food can give varying GI results 
(Wolever et al 2008). The glycemic response is affected by the nature of the carbohydrate 
(e.g. mono-, di- or polysaccharide), food processing (e.g. cooking and churning) and the 
presence of other macronutrients in the food (e.g. fat, protein and dietary fiber). Glucose has a 
high GI whereas fructose has a low GI (van Baak and Astrup 2009), this is because fructose is 
absorbed further down in the small intestine and it has to be converted into glucose before it 
can affect the insulin-secreting pancreas. The pancreas does not respond well to the fructose 
molecule because it lacks the glucose transporter 5 (GLUT5), which is the most effective 
transporter of fructose into cells (Sato et al 1996, Wood and Trayhurn 2003). Insulin secretion 
is also influenced by other hormones. Endocrine cells in the gastrointestinal tract secret 
glucose-dependent insulinotropic peptide (GIP) in response to glucose ingestion. This 
hormone increases the secretion of insulin at an early point, reducing the risk of high blood 
glucose level immediately after a meal (Song and Wolfe 2007). Fructose does not stimulate 
the release of GIP, and thus does not have the same insulin-increasing effect as glucose does.  
Amylose has low GI due to its linear chains of glucose molecules. The digestive enzymes can 
only release glucose molecules from the polysaccharide at the end of the chains, meaning that 
the linear amylose polysaccharide have only one site for the digestive enzymes to work on. 
Amylopectin has high GI due to its branched composition of glucose molecules, which 
provides the digestive enzymes with multiple sites from which to release glucose molecules 
from the polymer and finally into the blood stream (Wheeler and Pi-Sunyer 2008).  
The glycemic index of food may be a risk factor for developing metabolic syndrome. A low 
GI diet has been reported to reduce risk of developing metabolic disease, Type 2 diabetes, 
insulin resistance and coronary heart disease, and improved lipid status and inflammatory 
status, although not all studies have come to this conclusion. The different effects of high and 
low GI foods are proposed to be caused by the different rates of glucose uptake from the gut 
to the blood. The sharp increase in blood glucose after eating a high GI food triggers a large 
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insulin response from the pancreas and strongly inhibits the release of glucagon. This high 
insulin: glucagon ratio causes glucose uptake in liver and muscle to increase, as well as 
lipogenesis in adipose tissue. Release of glucose from the liver is inhibited, as well as release 
of free fatty acids (FFA) from adipose tissue. The high GI food is rapidly absorbed, putting an 
end to the release of nutrients into blood, but the effect of the high insulin: glucagon ratio 
persists. This causes blood levels to fall, often dropping below fasting levels (Fig 1.3). The 
resulting hypoglycemia triggers the release of glucagon, adrenaline and growth hormone. 
These hormones increase blood glucose levels by increasing gluconeogenesis and glycogen 
breakdown in the liver and decreasing glucose uptake in skeletal muscles. They also affect the 
adipose tissues by increasing lipolysis and the release of FFA, thus increasing the FFA in 
blood above normal levels. High FFA levels cause lipid accumulation in liver and skeletal 
muscles, which results in insulin resistance in these organs. Hyperglycemia, 
hyperinsulinemia, hypertriglyceridemia and insulin resistance are factors that contribute to the 
development of metabolic syndrome. Low GI foods are digested slower in the gut, and thus 
produce a less dramatic increase in blood glucose levels (Fig 1.3). They do not result in the 
hypoglycemic undershoot produced by the ingestion of high GI foods and the blood glucose 
level remains above fasted level for a longer period of time. This slower release of nutrients 
and more gradual drop in blood glucose levels allows the body to properly adjust insulin: 
glucagon hormone levels. Glucose and FFA in blood are maintained within normal range and 
thus do not disrupt insulin sensitivity. More stable hormone and nutrient levels are factors 
which can protect against the development of metabolic syndrome. Also, low GI diets puts 
less strain on the insulin-secreting β-cells in the pancreas compared to high GI diets. This may 
improve insulin secretion (Aston 2006). Still, many studies see no correlation between low GI 
diet and decreased body weight (Aston 2006, Aston et al 2008). 
 
Figure 1.3: The glycemic response curve to high glycemic index food (solid line) and low glycemic 
index food (dotted line). The line at the x-axis is the fasting blood glucose level. (Aston 2006) 
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Dietary fat 
Fat in the diet is either saturated (SFA), monounsaturated (MUFA) or polyunsaturated 
(PUFA). Saturated fatty acids (FA) have no double bonds in their carbon chain, 
monounsaturated FAs have one and polyunsaturated FAs have two or more double bonds. In 
addition to differing in the number of double bonds, FAs have different chain-length. The 
different types of FAs ingested in the diet are reflected in the plasma and tissue lipids and 
elicit different responses in the body. All cell membranes are composed of phospholipids with 
two FA tails, and the FA structure affects the flexibility and function of the cell. FA 
composition also affects gene expression and enzyme activities. SFAs are associated with 
increased risk of cardiovascular disease, reduced insulin resistance and increased visceral 
adiposity. Replacing SFAs with MUFAs or PUFAs is demonstrated to increase insulin 
sensitivity (Jucker et al 1999, Storlien et al 1987)  and reduce risk of cardiovascular disease 
(Harris 1997, Marik and Varon 2009, Riserus et al 2009). PUFAs are e.g. omega-3 (n-3) or 
omega-6 (n-6) fatty acids, depending on where the last double bond occurs on the carbon 
chain. n-3 FAs have their last double bond on the third carbon atom from the methyl end of 
the carbon chain (omega = end), whereas n-6 FAs have their last double bond on carbon atom 
number six. The number and placements of the other double bonds varies between different 
PUFAs. Fish oil is rich in the long-chained n-3 FAs eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) (Fig 1.4). These are collectively called omega-3 long-chained 
polyunsaturated fatty acids, or n-3 LCPUFAs (Buckley and Howe 2009, Schmitz and Ecker 
2008).  
 
Fig 1.4: Eicosapentaenoic acid (left) and docosahexaenoic acid (right). (Adapted from 
http://www.eufic.org/article/en/artid/The-importance-of-omega-3-and-omega-6-fatty-acids/) 
n-3 LCPUFAs are known to reduce the risk of cardiovascular disease. An increasing number 
of animal studies have also demonstrated that n-3 LCPUFAs reduce obesity when 
incorporated into high-fat diets, but few human studies are available (Buckley and Howe 
2009). n-3 LCPUFAs have also been demonstrated to be essential for normal growth and 
development, regulate lipid levels and immune system functions and have anti-inflammatory, 
antithrombotic, antiarrhytmic and vasodilatory properties. They are therefore proposed to 
have play a role in the prevention and management of dyslipidemia, insulin resistance, 
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metabolic syndrome and Type 2 diabetes (Lombardo and Chicco 2006). The main 
mechanisms of the anti-obesogenic effect of fish oil are summed up in figure 1.5. 
 
Figure 1.5: Fish oil increases fatty acid breakdown through PPARα-activation and SREBP-1c-
inactivation.The transcription factors PPARα and SREBP-1c are described below. (Kim et al 1999) 
Dietary protein 
There is a link between dietary protein and the development of obesity (Abete et al 2010), but 
the theme is too big to be discussed in this thesis. It is to be noted that in the absence of 
glucose in the diet, amino acids from both diet and muscle can be turned into glucose and 
ketone bodies to be used as fuel for the brain and red blood cells (Noguchi et al 1978). Also, 
exchanging dietary carbohydrates with protein is demonstrated to reduce feed efficiency in 
mice given n-6 PUFAs (Madsen et al 2008). 
 
1.3 ADIPOSE TISSUE 
Excess nutrients from the diet are converted into triglycerides (TGs) and stored in adipose 
tissue depots around the body. The adipose tissue functions as the body’s energy reserve, it 
also cushions the body and protects the internal organs. Adipose tissues can be either white or 
brown. Brown adipose tissue (BAT) gets its name from the increased number of mitochondria 
present in the adipocytes, giving the cells a brown color. BAT has the capacity of turning fat 
into heat, and thus increasing the body temperature. This is especially valuable for animals 
with high surface area and low body weight, including human babies. As babies grow beyond 
approximately 10 kg, the brown adipose tissue mass is reduced and mostly white adipose 
tissue (WAT) is left. Some remaining clusters of brown adipocytes are found along the spine 
(paravertebral), neck (cervical) and shoulder blades (supraclavicular) in the adult human 
(Gesta et al 2007).  
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There are two main types of white adipose tissue depots; subcutaneous and visceral. The 
subcutaneous adipose tissue is located under the skin, distributed all over the body. The 
visceral fat depot is located around internal organs, which contains it to the stomach area. In 
obese humans, as well as other animals, adipose tissues expand in both these depots as well as 
in other adipose tissue depots around the body (Fig 1.6). It accumulates around the heart, 
kidneys and the connective tissue around blood vessels (Ouchi et al 2011). Visceral fat 
promotes a higher risk of developing metabolic syndrome compared to fat depots on hips and 
thighs (Gesta et al 2007). 
 
Figure 1.6: Different adipose tissues around the body. Pulmonary adipose tissue, periadventitial 
adipose tissue, perirenal adipose tissue, bone marrow adipose tissue, epicardial adipose tissue, 
subcutaneous adipose tissue and visceral adipose tissue. (Ouchi et al 2011) 
The main components of the adipose tissue are the adipocytes. They store energy in the form 
of TGs and exert endocrine activity. Other cell types present in adipose tissue include 
adipocyte precursor cells, fibroblasts, vascular cells and immune cells (Fig 1.7). These cells 
constitute the connective tissue of the adipose tissue. Blood vessels are required for the flow 
of nutrients and oxygen to the adipose tissues, they also distribute hormones and adipokines to 
and from adipocytes. Macrophage cells and T-cells determine the inflammatory and immune 
status of the adipose tissue (Ouchi et al 2011). 
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Figure 1.7: Simplified illustration of adipose tissue containing adipocytes, pre-adipocytes, T-cells, 
macrophages, fibroblasts, blood vessels and capillaries. (Ouchi et al 2011) 
 
1.4 ENZYMES INCREASING LIPOGENESIS 
There are many enzymes linked to adipogenesis, not all will be discussed here. In this study 
we measured the mRNA levels of SREBP-1c, ACC1, ACC2, FAS, SCD1, DGAT and 
PPARγ, so these enzymes will be the main focus of this section. 
SREBP-1C: The gene Srebp1c codes for the Sterol regulatory element-binding protein-1c 
(SREBP-1c). This is a transcription factor which regulates the mRNA expression levels of 
lipogenic enzymes, such as fatty acid synthase (FAS), Acetyl-CoA carboxylases (ACCs) and 
Stearoyl-CoA Desaturase 1 (SCD1) (Horton et al 1998, Jump et al 2005).  
SREBPs are located in the endoplasmatic reticulum as inactive precursors. After transport to 
the Golgi apparatus they are cleaved into active forms and subsequently translocated into the 
nucleus. Here, they activate the transcription of lipogenic genes. This means that the level of 
Srebp1c mRNA is not necessary a true measurement of the amounts of active SREBP-1c 
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enzyme present in the cell. SREBP-1c is the predominant type of SREBP-1 in both human 
and rodent liver and plays an important role in the metabolism of fatty acids and cholesterol.  
Levels of SREBP-1c are influenced by diet and hormones. Food intake, especially sucrose, 
and insulin increases the expression of SREBP-1c. Insulin resistance in patients with Type 2 
diabetes leads to increased levels of insulin in the blood. This leads to elevated levels of 
hepatic SREBP-1c, which again increases the expression of lipogenic genes and causes fat to 
accumulate in the liver. Fatty liver can result in the development fibrosis, cirrhosis and liver 
failure (Horton et al 2002). The glucagon hormone is shown to decrease the levels of SREBP-
1c, but it can also be done by diet. PUFAs reduce the levels of Srebp1c mRNA (Xu et al 
2001) and they are shown to disrupt the inactive precursors of SREBP-1c before they reach 
the nucleus (Yahagi et al 1999). This down-regulates the levels of mature SREBP-1c and thus 
reduces the levels of lipogenic enzymes in the liver (Osborne 2000). SREBP-1c is not the sole 
regulator of the expression of lipogenic enzymes, studies have shown that SREBP-1c 
deficient mice have reduced, but not eliminated expressions of lipogenic genes, e.g. ACCs 
and FAS (Liang et al 2002). 
ACC1 and ACC2: Acetyl-CoA carboxylases 1 and 2 (ACC1 and ACC2) are lipogenic 
enzymes. They catalyze the synthesis of malonyl-CoA, which is a substrate for fatty acid 
synthesis and also a regulator of fatty acid breakdown. The Acc1 and Acc2 genes are generally 
expressed in all tissues (Abu-Elheiga et al 1997, Castle et al 2009). Both genes are regulated 
by multiple promoters, which are influenced by both hormones and diet. A low-fat diet rich in 
carbohydrates induces the synthesis of ACC1 and ACC2. Insulin up-regulates the expression 
of Acc1 through the transcription factor SREBP-1c, while glucagon down-regulates it. ACC 
activity is also affected by glucose levels. High glucose levels activate carbohydrate response 
element binding protein (ChREBP), which is a transcription factor for both Acc and Fas (Ishii 
et al 2004, Kim 1997). Low glucose levels leads to the activation of AMP-activated protein 
kinase (AMPK), which inactivates the ACC enzyme by phosphorylation (Park et al 2002).  
The malonyl-CoA molecules formed by the different ACC enzymes are segregated within the 
cell. The malonyl-CoA generated from the ACC1 enzyme is utilized by FAS for de novo 
synthesis of fatty acids in the cytosol. The ACC2-generated malonyl-CoA is an inhibitor of 
the carnitine palmitoyltransferase 1 (CPT1, described below) mitochondrial enzyme. This 
inhibits the breakdown of fatty acids by preventing the transfer of acyl-CoA groups from the 
cytosol into the mitochondria for β-oxidation (Wakil and Abu-Elheiga 2009).  
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Figure 1.8: Interplay between the enzymes ACC1, FAS, CPT1 and ACC2 in fatty acid synthesis, β-
oxidation and tricarboxylic acid cycle, as well as the metabolites glucose, acetyl-CoA, malonyl-CoA, 
palmitate, acyl-CoA, fatty acids and ketone bodies. (Wakil and Abu-Elheiga 2009) 
FAS: Fatty acids are built from two-carbon building blocks, assembled by the fatty acids 
synthase (FAS) enzyme. The synthesis of fatty acids requires acetyl-CoA, malonyl-CoA and 
NADPH. Malonyl-CoA provided by the ACC1 enzyme is the C2 donor in the de novo 
synthesis of fatty acids and it also inhibits fatty acid oxidation (Kim 1997, McGarry et al 
1977). As previously mentioned, FAS is under control of the SREBP-1c transcription factor, 
it is thus under indirect influence of both hormonal and dietary factors (Xu et al 1999, Xu et al 
2001). The interplay between ACC1, ACC2, CPT1 and FAS is shown in figure 1.8. 
SCD1: Stearoyl-CoA Desaturase 1 (SCD1) is the rate-limiting enzyme catalyzing 
monounsaturated fatty acids. It uses palmitoyl-CoA and stearoyl-CoA as substrates to form 
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palmitoleyl-CoA and oleyl-CoA, respectively. These fatty acids are subsequently used to form 
triglycerides for storage of fat or phospholipids for constructing cell membranes. Obese mice 
with high levels of Scd1 are reported to suffer from insulin resistance and fatty liver. Mice 
deficient in SCD1 are on the other resistant to obesity (Miyazaki et al 2009). The SCD1 gene 
is expressed in various tissues, including liver and adipose tissues in both mice and humans. 
SREBP-1c is identified as one of many promoters of SCD1, which means it is under the 
influence of insulin and also diet (Mauvoisin and Mounier 2011). Polyunsaturated fatty acids 
are known to be inhibitors of SCD1 gene expression (Ntambi 1999).  
DGAT: Acyl Coa: diacylglycerol acyltransferase (DGAT) is an enzyme with a central role in 
the metabolism of glycerolipids. DGAT synthesizes triacylglycerol by using diacylglycerol 
and fatty acyl-CoA as substrates (Lehner and Kuksis 1996). Regulation of DGAT enzymes is 
complex and not fully understood. It is not reported to be under control of the SREBP-1c 
transcription factor, but it may be influenced by CCAAT enhancer-binding protein α 
(C/EBPα) or peroxisome proliferator-activated receptor γ (PPARγ), which are transcription 
factors which controls several other lipogenic genes (Yen et al 2008).  
PPARγ: The peroxisome proliferator-activated receptor γ (PPARγ) transcription factor is 
necessary for adipocyte differentiation from fibroblasts, and also for maintaining the mature 
adipocyte. Expression of the PPARγ gene is promoted by C/EBPα. It is also regulated by 
several other pro- and anti-adipogenic factors, including SREBP-1c, as illustrated in figure 
1.9. There are two isoforms of the PPARγ enzyme, PPARγ1 and PPARγ2. The Pparγ1 and 
Pparγ2 mRNAs are transcribed from the same DNA sequence, the different isoforms are 
generated through different promoter usage and alternative splicing of the pre-mRNA. Both 
are induced during adipogenesis, but PPARγ2 is found to be somewhat more efficient at 
promoting adipogenesis. PPARγ1 is also found in other cell types, for example macrophages. 
The PPARγ enzymes have to be activated by ligand to be transferred into the nucleus and 
induce adipogenesis (Rosen and MacDougald 2006). This means, like in the case of SREBP-
1c, that the levels of Pparγ mRNA present in the tissue is not necessarily a good measurement 
of the amount of active PPARγ. Medicines that bind to PPARγ, e.g. rosiglitazone, and activate 
them have been used to treat Type 2 diabetes. Activated PPARγ increase insulin-stimulated 
glucose transport into the cells, which decrease hyperglycemia in diabetic patients. Activation 
of PPAR γ also leads to stimulation of adipogenesis, so even if PPARγ activating treats a 
symptom of Type 2 diabetes, it may aggravate obesity which is often one of the underlying 
factors for Type 2 diabetes development. It also may have adverse effects on skeletal 
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metabolism. As illustrated in figure 1.14, adipocytes and osteoblasts are derived from the 
same precursor cells. PPARγ activation leads to the formation of adipocytes in the skeleton, 
long-term use of rosiglitazone may thus lead to bone loss (Kawai and Rosen 2010, Wei et al 
2010). Considering the risk of adverse effects when taking any form of drug, dietary strategies 
aimed to prevent and treat Type 2 diabetes is highly recommendable.  
 
Figure 1.9: PPARγ is central in the regulation of adipogenesis. Black lines indicate effects on gene 
expression, blue lines are effects on protein activity. (Rosen and MacDougald 2006) 
 
1.5 ENZYMES INCREASING FATTY ACID BREAKDOWN 
Fatty acid breakdown occurs through lipolysis and β-oxidation. Lipolysis is the hydrolyzation 
of triacylglycerol (TAG) into free fatty acids (FFAs). These free fatty acids are attached to 
coenzyme A, forming the acyl-CoA molecule. Acyl-CoA is broken down into acetyl units by 
β-oxidation in the cells mitochondria. This yields energy in the form of ATP-molecules. The 
metabolism of a FFA is illustrated in figure 1.10 (note that the FFA is labeled NEFA, which is 
the same thing). The oxidation of fat is highly regulated by diet, hormones and energy 
demands (Eaton 2002). Only the enzymes which mRNA levels were measured in this study 
will be described in this section. That includes PPARα, PPARδ, CPT-1A, CPT-2, HMGCS2 
and ACO.  
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Figure 1.10: Metabolism of non-esterified fatty acid (NEFA or FFA) in a generic cell. Fuel is generated 
in the mitochondria by the tricarboxylic acid cycle (also known as the citric acid cycle and Krebs cycle) 
of carbohydrates and β-oxidation of fatty acids. (Eaton 2002) 
PPARα and PPARδ: Peroxisome proliferator-activated receptors (PPARs) are a superfamily of 
transcription factors that coordinate lipid metabolism. Like in the case of SREBP-1c and 
PPARγ, these transcription factors have to be activated by ligand prior to transport into the 
nucleus to exert their effect on gene transcription. PPARs are in several studies shown to be 
activated by unsaturated fatty acids, such as PUFAs (Chawla et al 2001, Hostetler et al 2005). 
Pparα is highly expressed in liver, kidney, heart and brown adipose tissue. In the liver, 
PPARα affect the uptake of fatty acids through membranes, fatty acid activation, intracellular 
trafficking, oxidation and ketogenesis as well as triglyceride storage and lipolysis. Among the 
many target genes for PPARα is the Acyl-CoA oxidase (Aco) gene, which is the rate-limiting 
enzyme in peroxisomal long-chain fatty acid oxidation (Rakhshandehroo et al 2010). Pparδ is 
equally expressed in all tissues and was until recently regarded as a housekeeping gene. The 
role of PPARδ is not fully described, but Pparδ-knockout mice have reduced adipose tissue 
mass, implying its involvement in adipogenesis (Barak et al 2002). More recent studies have 
proposed that PPARδ favors the oxidation of fat. Activation of PPARδ led to reduced adipose 
tissue mass and improved adiposity, whereas PPARδ-deficient mice were prone to obesity on 
a high-fat diet (Wang et al 2003). PPARδ is also shown to activate target genes associated 
with oxidation of fat in cell cultures, including Cpt1 (Alaynick 2008). 
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CPT: Carnitine palmitoyltransferase 1A (CPT1A) is found in liver cells, whereas the isoform 
CPT1B is found in muscle tissue. The enzyme is located on the mitochondrial membrane, 
with its active site facing the cytosol (van der Leij et al 1999). Here the CPT1A controls much 
of the hepatic β-oxidation as the rate-controlling enzyme, transferring long-chain acyl-
moieties of acyl-CoA from coenzyme A to carnitine. The acyl-carnitine is then transferred 
from the cytosol to inside the mitochondria by the carnitine-acylcarnitine transporter. Inside 
the mitochondria, the action of CPT1 is reversed by CPT2, which exchanges the carnitine for 
CoA, regenerating acyl-CoA. The acyl-CoA released from CPT2 is broken down into acetyl-
CoA by β-oxidation (Rufer et al 2009). The actions of CPT1 and CPT2 are illustrated in 
figure 1.11. 
 
Figure 1.11: Transfer of acyl-CoA from cytosol into mitochondria. (Rufer et al 2009) 
CPT1 is inhibited by malonyl-CoA, the product of ACC2, as described above (Eaton 2002). 
Transcription of the Cpt1a gene is reduced by insulin (Park et al 1995). Cpt1a is up-regulated 
by the presence of LCFA, such as PUFAs. This up-regulation can be done by the transcription 
factors PPARα and peroxisomal proliferator-activated receptor gamma coactivator-1 (PGC-
1α) (Napal et al 2005). CPT2 is an enzyme with good substrate capacity and is not considered 
to be a rate-limiting enzyme (Eaton 2002). 
HMGCS2: The Hydroxymethylglutaryl CoA synthase 2 (Hmgcs2) gene codes for a 
mitochondrial enzyme that controls the hydroxymethylglutaryl CoA-cycle (HMG-CoA cycle). 
Cytosol 
 
Mitochondria 
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This gene is also induced by PPARα (Vila-Brau et al 2011). The HMG-CoA cycle converts 
acetyl-CoA from the β-oxidation into the ketone bodies acetoacetate, β-hydroxybutyrate and 
acetone. This is known as ketogenesis. Ketogenesis occurs in the liver and the ketone bodies 
can be used as substitutes for glucose (Hegardt 1999). 
ACO: Acyl-CoA oxidase (ACO) is located in the peroxisome and is highly expressed in liver. 
It specifically oxidizes long-chain fatty acids, including PUFAs. PPARα is an inducer of Aco, 
demonstrated by the fact that PPARα-knockout mice do not have raised levels of Aco in the 
presence of PUFAs (Duplus and Forest 2002). The rare disorder of Acyl-CoA oxidase 
deficiency causes the hepatic peroxisomes to increase in size. It also causes very long chain 
fatty acids (VLCFA) to accumulate in serum and tissues (Poll-The et al 1988). 
 
1.6 GLUCONEOGENESIS IN LIVER  
This section will focus on the enzymes PCK1 and PGC-1α, which were measured in the liver 
of our animals. PGC-1α was also measured in adipose tissues, but its function in adipose 
tissues is quite different. This is described in section 1.10. 
PCK1: During fasting, glucose levels are maintained through gluconeogenesis. In Type 2 
diabetic patients, gluconeogenesis is consistently upregulated, contributing to high blood 
glucose levels. Phosphoenolpyruvate carboxykinase (PCK1, also known as PEPCK) is the 
rate-limiting enzyme in gluconeogenesis. Pck1 is upregulated by the hormones glucagon and 
glucocorticoids (Herzig et al 2001) and is thus under dietary influence. 
PGC-1α: PPARγ coactivator 1 (PGC-1) is a gene coactivator. Whereas transcription factors 
bind to DNA and thereby control the transcription of a gene, coactivators can modify 
chromatin, unwind DNA and recruit RNA polymerase II. PGC-1α interacts with and 
coactivates a number of transcription factors and nuclear receptors, influencing energy 
metabolism and thermogenesis. Pgc1α expression is regulated by PGC-1α itself, via 
interaction with myocyte enhancer factor-2 (MEF2). PGC-1α activity is regulated by 
posttranslational modifications, including phosphorylation and deacetylation (Lin et al 2005). 
Active PGC-1 potentiates glucocorticoid induction of Pck1 transcription. Obese mice have 
elevated blood glucose during fasting and are also shown to have elevated levels of Pgc1α 
and Pck1. Hyperglycemia is also seen in patients with Type 2 diabetes, and it is suggested that 
PGC-1α and PCK1 contributes to the pathogenesis of this disease (Yoon et al 2001).  
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1.7 HEPATIC AMINO ACID DEGRADATION  
Many amino acids can be converted into alanine and alanine can be converted into glucose. In 
obese, insulin-resistant patients, amino acid degradation is upregulated to increase 
gluconeogenesis. This results in hyperglycemia seen in Type 2 diabetic patients. This section 
will focus on the enzymes AGXT, GOT, GPT1 and CPS1. 
AGXT: The Agxt gene codes for the peroxisomal enzyme alanine-glyoxylate aminotransferase 
(AGXT) in the liver. It is induced by glucagon and cyclic AMP. In mice, it breaks down L-
amino acids and glyoxylate into pyruvate and glycine. The pyruvate can be used for 
gluconeogenesis (Noguchi et al 1978). 
GOT: The glutamate oxaloacetate transaminase (GOT) enzyme exists as two similar enzymes, 
GOT1 is located in the cytosol while GOT2 is in the mitochondria. The genes coding for the 
different enzymes are quite homologous. The mitochondrial GOT2 is predominant in liver. 
This enzyme catalyzes the formation of oxaloacetate from glutamate. Oxaloacetate is an 
intermediate in the tricarboxylic acid cycle, but can also be used in gluconeogenesis.  
GPT: The glutamate pyruvate transaminase (Gpt1) gene codes for the enzyme alanine 
aminotransferase 1 (ALT1). Gpt1 is mainly expressed in liver, bowel and white adipose tissue 
(Jadhao et al 2004). The ALT enzymes transfer the α-amino group from the glutamate amino 
acid to a pyruvate molecule. This forms the amino acid alanine, which can be transformed 
into glucose. This is useful during fasting, when blood glucose is low (Felig 1973), but for 
obese patients with insulin resistance it leads to hyperglycemia. 
CPS1: The gene Cps1 codes for the mitochondrial enzyme Carbamoyl-phosphate synthase 1 
(CPS1). This enzyme catalyzes the first committed step of the urea cycle, which removes 
excess nitrogen in the form of urea from the cells. It uses ammonia and bicarbonate to 
synthesize carbamoyl phosphate, which is subsequently transformed into urea (Shambaugh 
1978). Upregulation of this gene is a sign of increased amino acid breakdown. 
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1.8 CYCLIC AMP SIGNALING 
Cyclic adenosine monophosphate (cAMP) is a signal of starvation. It is generated by 
adenylate cyclases from ATP at the cytosolic side of the cells plasma membrane (Houslay and 
Adams 2003). Elevated cAMP levels induces gluconeogenesis in liver and lipolysis in adipose 
tissue (Madsen and Kristiansen 2010). cAMP levels could not be measured in this experiment 
due to the fast degradation of the molecule in dead tissue, so we measured the expression 
levels of Crem, RIα, RIIβ and Pde4c. Their function will be briefly described in this section.   
PKA isoforms - RIα and RIIβ: It is suggested that cAMP-dependent protein kinase A (PKA) is 
required for cAMP-induced gene transcription (Montminy 1997). The PKA is assembled from 
two regulatory (R, α and β) and two catalytic units. The holoenzyme PKA is activated by 
cAMP, which releases the two catalytic units from the regulatory units. The catalytic units 
exert several effects on metabolism, mainly increasing lipolysis and inducing 
gluconeogenesis. In mice, there are two isoforms of the regulatory subunits, RI and RII. The 
RIIβ isoform is expressed in both white and brown adipose tissues in mice. Mice with 
disrupted RIIβ isoform are protected against diet-induced obesity. The loss of the RIIβ 
isoform in these mice leads to a compensatory increase in the RIα-isoform of PKA. The RIα-
isoform eagerly binds to cAMP, so this form of PKA is more easily activated by cAMP 
compared to the wild-type enzyme. Active PKA catalytic units phosphorylate and thus 
activate enzymes involved in metabolism. They increase the activity of uncoupling protein 
(UCP), which increases the metabolic rate and elevates body temperature. The higher ratio of 
RIα compared to RIIβ leads to healthy, lean mice which are protected from diet-induced 
obesity and hepatic steatosis (Cummings et al 1996).  
CREM: cAMP-responsive element modulator (Crem) is an enhancer of genes that are 
transcribed in response to increased cAMP-levels. It is induced by several transcription 
factors, including cAMP-responsive element binding protein (CREB) (Montminy 1997). Both 
CREM and CREB bind to a DNA sequence known as the cAMP responsive element (CRE), 
which is present in the regulatory region of target genes. CREM is activated by PKA by 
phosphorylation and is thus regulated by cAMP (de Groot et al 1994, Montminy 1997). The 
Crem mRNA can be alternatively spliced into both transcriptional activators and repressors 
(Inada et al 1999).  
PDE: cAMP phosphodiesterases (PDEs) have a regulatory role in the sense that it is the only 
enzyme capable of degrading cAMP. PDEs are thus located at multiple sites in the cell, 
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including the cytosol, nucleus, various membranes and in the cytoskeleton. In the PDE 
families, there are over 30 isoforms capable of degrading cAMP. The PDE4 family consists of 
four subfamilies, the PDE4a-d. These generate over 16 isoforms. Mice with inactive PDE4s 
exhibits decreased inflammation (Houslay and Adams 2003). 
 
1.9 INFLAMMATION MARKERS IN ADIPOSE TISSUE 
Inflammation of the adipose tissue is a chronic, low inflammatory state that occurs when 
adipocytes enlarge in size and recruit macrophages. Enlargement of adipocyte size is a result 
of accumulation of excess triglycerides. Large adipocytes release more free fatty acids 
(FFAs), especially saturated fatty acids, which bind to macrophages at the macrophage toll-
like receptor-4 (TLR-4). Saturated fatty acids from diet activate the TLR-4, while 
polyunsaturated fatty acids block it. Activated TLR-4 causes the macrophages to change their 
phenotype from M2, which is a partially activated state, to M1, which is a constant activated 
state. M1 macrophages secret higher levels of tumor necrosis factor α (TNFα). The TNFα 
binds to adipocytes, causing them to increase lipolysis and express various pro-inflammatory 
genes, e.g. CC-chemokine ligand 2 (CCL2, also known as monocyte chemotactic protein-1, 
MCP-1) (Ouchi et al 2011). The development from normal adipose tissue to inflamed adipose 
tissue is illustrated in figure 1.13. Inflammation of adipose tissue is worse in visceral fat 
compared to the subcutaneous fat depots (Gesta et al 2007).  
The vicious cycle of enlargement of adipose tissue and activation of macrophages also leads 
to reduced expression of adiponectin, a hormone excreted from adipose tissue with regulatory 
effects on glucose and fatty acid metabolism. Adiponectin has positive effects on the 
development of obesity, Type 2 diabetes and metabolic syndrome. Dietary fish-oil, rich in 
long-chain polyunsaturated fatty acids, is associated with increased levels of adiponectin in 
mice (Hajer et al 2008). The n-3 fatty acids EPA and DHA are also associated with reduced 
levels of inflammatory macrophages. This occurs through activation of the G protein-coupled 
receptor 120 (GPR120), which increases the gene expression of the anti-inflammatory M2 
macrophage phenotype and reduces the gene expression of the proinflammatory M1 
phenotype (Oh et al 2010). 
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Figure 1.12: M1 macrophages generate large amounts of pro-inflammatory factors. This leads to a 
dysfunctional adipose tissue and the evolvement of crown-like structures, which is dead adipocytes 
with M1-type macrophages assembled around them. (Ouchi et al 2011) 
The adipocyte dysfunction illustrated in figure 1.12 can lead to Type 2 diabetes. High levels 
of FFAs secreted from adipocytes in obese patients inhibit insulin secretion from the 
pancreas. This is done in several ways; FFAs can open β-cell potassium channels, which 
reduce insulin secretion. FFAs also enhance the expression of uncoupling protein 2 (Ucp2), 
which diminishes ATP-production required for insulin secretion. FFAs are also shown to 
induce apoptosis of β-cells through endoplasmic stress response and by inhibiting the 
expression of anti-apoptopic factor Bcl-2. Also, tumor necrosis factor α (TNFα) secreted from 
inflamed adipose tissue induces pro-apoptopic NO production and inhibits insulin signaling in 
the β-cell. Obese patients may be leptin resistant, which also aggravate the insulin signaling. 
Leptin is able to reduce apoptosis through inhibition of nitric oxide (NO) production. Patients 
with leptin resistance do not gain from the anti-apoptopic effect of the leptin hormone.  
FFAs, TNFα and leptin resistance together reduces insulin secretion from the pancreas, which 
contributes to the development of Type 2 diabetes, as illustrated in figure 1.13 (Hajer et al 
2008).  
In this study, we measured the inflammation markers Ccl2, Serpine1, Cd68 and Emr1 in 
epididymal and inguinal white adipose tissues.  
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Figure 1.13: Adipocyte dysfunction leads to Type 2 diabetes. (Hajer et al 2008) 
CCL2: Obese mice as well as humans have elevated levels of Ccl2 in adipose tissue. This 
leads to macrophage recruitment to adipose tissue and increased inflammation. It also 
promotes glucose intolerance and insulin resistance, as seen in Type 2 diabetes. CC-
chemokine receptor 2 (Ccr2) is the receptor for CCL2. Mice with Ccr2 deletion gain as much 
weight as wild-type mice on a high-fat diet, but do not have adipose tissue inflammation and 
maintain insulin sensitivity (Ouchi et al 2011). 
Serpine1 (also known as PAI-1): PAI-1 is the human homologue to serine peptidase 
inhibitor (Serpine1) in mice. Serpine1/PAI-1 is a regulator of fibrinolysis, the breaking down 
of blood clots. It is produced by visceral adipocytes and is shown to be regulated by TNFα, 
insulin, FFAs and glucocorticoids in vitro. Elevated levels of circulating PAI-1 are associated 
with increased risk of damage to the blood vessels. This is caused by the forming of small 
blood clots and plaque, resulting in narrowing of the blood vessels and small ruptures which 
attracts macrophages. Pai1 is shown to be elevated in obese patients suffering from metabolic 
disease (Hajer et al 2008). 
CD68: Macrosialin is the mouse analog to human Cluster of Differentiation (CD68). They are 
80% similar and are both expressed by macrophages (Holness et al 1993). Its function is still 
uncertain, but it is found almost exclusively on macrophages (Kurushima et al 2000). 
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EMR1 (also known as F4/80): EGF-like module-containing, mucin-like hormone, receptor-
like sequence 1 (EMR1) is the human analog to the F4/80 found in mice. It is a monoclonal 
antibody that recognizes cell surface glycoprotein on macrophages. The macrophages regulate 
their immune responses through these cell surface receptors (McKnight et al 1996). 
 
1.10 GENES EXPRESSED IN BROWN AND WHITE, BROWN-LIKE ADIPOCYTES 
Adipocytes evolve from stem cells. The stem cells develops into mesenchymal stem cells 
which then commits into becoming osteocytes (bone), adipocytes (fat) or myocytes (muscle). 
The undifferentiated adipoblast precursor cell is influenced by different transcription factors 
and subsequently differentiates into a white or brown adipocyte, as illustrated in figure 1.14.  
 
Figure 1.14: The evolvement of adipocytes from mesenchymal stem cells. (Gesta et al 2007)  
White adipocytes accumulate large amounts of fat, they have very little cytoplasm because the 
lipid droplet containing triglycerides occupies up to 95% of the cell volume. Brown 
adipocytes have small lipid droplets distributed around their considerable cytoplasm. The 
brown color of these cells is caused by the large amount of mitochondria present in the cell. 
Brown adipocytes have the capacity to burn fat and thus turning it into heat due to the 
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increased number of mitochondria (Gesta et al 2007). Studies have stated that brown and 
white adipocytes can change phenotypes. White and brown adipocytes accumulate in different 
tissues, but the white adipose tissue contains some brown adipocytes and vice versa. The 
phenotype of an adipocyte is able to change, a white adipocyte can acquire a brown-like 
phenotype through the increase of PGC-1α (Tiraby et al 2003) . 
In this study, we measured the expression levels of Pgc1α and Ucp1 in both brown and white 
adipose tissues. Dio2, Cox2, and Rip140 were measured only in brown adipose tissues.  
PGC-1α: Whereas elevated levels of Pgc1α in liver and blood is not a good thing, Pgc1α 
expression in white and brown adipose tissue is. PGC-1α in adipocytes is a transcriptional 
coactivator for uncoupling protein-1 (UCP1), which stimulates lipid oxidation, mitochondrial 
β-oxidation and heat production (Lin et al 2005). This increases energy expenditure and can 
protect against obesity. PGC-1α is also a coactivator for the NAD-dependent deacetylase 
sirtuin-3 (SIRT3), which activates the expression of UCP1 and other thermogenetic genes 
(Giralt et al 2011). Pgc1α is rapidly expressed in adipocytes by exposure to cold environment, 
resulting in maintenance of body temperature. Mice deficient in PGC-1α are extremely cold 
sensitive. PGC-1α is primarily found in brown adipocytes, where it may have a role in the 
development of brown adipocytes (Lin et al 2005).  
Dio2: In brown adipose tissue, Type II iodothyronine deiodinase (Dio2) converts the inactive 
thyroid hormone prohormone thyroxin (T4) into the active form triiodothyronine (T3). T3 
reduces the half-life of UCP1 in the brown adipocyte, thereby increasing the cells capacity to 
turn fat into heat. Dio2 is expressed in brown adipose tissue and is induced by cold exposure. 
It is also induced by both insulin and glucagon, as well as norepinephrine. The activity of 
Dio2 is increased by cAMP-dependent protein kinase (PKA) (Bianco et al 2002).  
RIP140: Receptor-interacting protein 140 (RIP140) is a nuclear receptor corepressor with 
control over lipid metabolism. It represses the expression of Ucp1, leading to reduced 
oxidation of fat in brown adipocytes and increased accumulation of fat. RIP140-null mice are 
lean and resistant to diet-induced obesity (Christian et al 2005).  
CytCox: Cytochrome c oxidase (CytCox) is an enzyme complex located at the inner 
mitochondrial membrane. It is derived from both nuclear and mitochondrial DNA, see figure 
1.15. Cox2 is among the mitochondrial derived subunits. ATP production in mitochondria is 
driven by a proton gradient across the inner mitochondrial membrane. This proton gradient is 
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generated from electrons from NADH or FADH2. These electrons are passed through redox 
systems and finally transferred to molecular oxygen by CytCox. CytCox is therefore vital for 
the mitochondrial function (Mick et al 2011). 
 
Figure 1.15: CytCox is assembled from subunits derived from both nuclear and mitochondrial DNA. 
Nuclear DNA is transcribed into mRNA and translated into precursor proteins in the cytosol. These 
precursor proteins are translocated to the inner mitochondrial membrane. Mitochondrial DNA is 
transcribed into mrRNA and subsequently translated into proteins at the inner mitochondrial 
membrane. After insertion of both nuclear- and mitochondria-derived protein into the membrane, these 
subunits are assembled into the functional CytCox complex. (Mick et al 2011) 
 
1.9 ACCUMULATION OF TRIGLYCERIDES IN LIVER, MUSCLE AND PLASMA 
Accumulation of triglycerides in the liver leads to hepatic steatosis, or fatty liver disease. 
Non-alcoholic fatty liver disease is a common liver disease found in obese patients with Type 
2 diabetes. It is primarily caused by the release of triglycerides from adipose tissue into the 
blood stream, which causes it to accumulate in liver and muscle (Fig 1.16). Steatosis can 
evolve into serious liver damage, also TG accumulation in liver and muscle is associated with 
reduced insulin sensitivity. It is still unclear whether TG accumulation causes insulin 
resistance or the other way around.  Currently, there is no treatment for steatosis, apart from 
the life style modifications recommended to obese patients (Ferre and Foufelle 2010).  
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Figure 1.16: Contributions of various metabolic pathways to hepatic steatosis in obese humans. The 
major contributor to triglyceride accumulation in the liver is the increased release of FFA from adipose 
tissue. (Ferre and Foufelle 2010) 
 
1.10 SUMMARY AND AIM OF THE STUDIES 
Obesity is caused by excess nutrients. Type of nutrients can influence how much fat is stored 
and where the body stores it. Visceral adipose tissue is more prone to inflammation compared 
to subcutaneous fat depots. White adipocytes stores fat, whereas brown adipocytes can turn 
fat into heat.  
Carbohydrates exist in several forms. Fructose does not instantly raise insulin levels, in 
contrast to glucose. Glucose exists as monosaccharides, polysaccharides and as a part of 
disaccharides, e.g. sucrose.  
Fatty acids are more than mere energy. They influence our health by incorporation into 
cellular membranes and can act as ligands for transcriptional factors and thus influence the 
expression of lipogenic, lipolytic, gluconeogenetic and inflammatory genes.  
PUFAs are demonstrated in several studies to attenuate diet-induced obesity. On the other 
hand, sucrose and high GI diets are demonstrated to be obesogenic. The aim of this study is to 
investigate whether the obesogenic effects of sucrose and high GI diet, which we know are 
major components of most people’s diet, can be attenuated by fish oil. We also want to 
investigate whether the fructose moiety of the sucrose molecule is obesogenic, antiobesogenic 
or neither. Finally, we want to see which diet, if any, is most likely to be healthy for humans. 
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2. MATERIALS AND METHODS 
2.1 ANIMAL MODEL 
Our choice of animal model fell on the C57BL/6J mouse, also called black-six mouse. This 
mouse has proved itself as a good model for human metabolic syndrome because it easily 
develops diet-induced obesity, along with hyperinsulinemia, hyperglycemia and hypertension. 
Black-six mice develop central obesity, which is also common in obese humans with Type 2 
diabetes (Collins et al 2004). Male mice were chosen over female because males have an 
extra visceral fat depot, the epididymal fat, around their testes. It is also prohibited to keep 
female mice in separate cages, whereas males are best kept in single cages. In this experiment 
it was vital to keep the animals in separate cages to record each animals feed intake.  
The mice were kept in accordance with guidelines provided by The Norwegian Animal 
Research Authority. The experiment was approved by the Norwegian State board of 
biological experiments.   
 
Figure 2.1 C57BL/6J mouse. From http://www.taconic.com/wmspage.cfm?parm1=760 
 
2.2 EXPERIMENTAL SETUP 
46 male mice were purchased from Scanbur AS (Nittedal, Norway). On the 17
th
 of 
September, they were weighed and separated into single cages. The mice then had three 
weeks to settle into their new environment, partly due to a delay in the arrival of the 
experimental feed. On October the 2
nd
, the mice were weighed again and five mice at the 
bottom and top of the weight scale were removed from the experiment, leaving 36 mice 
weighing from 26.32 and 30.90 gram. The mice were then between 13 and 14 weeks old. The 
mice were fed chow-diet during their acclimatization period and they had free access to tap 
water at all times. The mice were kept in a 12h light/dark cycle at 22-25 °C and 40-50% 
humidity. The bedding was wooden chip bedding (Scanbur Bedding Aspen, Norway). They 
were fed almost exclusively by me, at the same time, every single day. The animals were 
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observed for health problems and abnormal behavior every day. Water was changed every 
other day and their cages cleaned every 14
th
 day. Body weight was recorded twice a week, 
Mondays and Thursdays. At the beginning of the trial, the 36 mice were divided into 6 
groups, with 6 animals in each group. They were divided based on starting weight to achieve 
the same mean weight in each group.  
 
2.3 DIETS 
The 6 groups were given different diets. Diets were purchased from Ssniff (Spezialdiäten 
GmbH, Soest, Germany) and stored at -20 °C. All diets contained the same amount and type 
of protein, ash, fiber, vitamins and trace elements.  
Group 1 was given low energy standard chow diet, containing low amounts of fat and high 
amounts of carbohydrates. Group 2-6 were all given high amounts of fish oil in combination 
with different types of carbohydrates. The fish oil diets contained 62 g/kg n-3 PUFAs, thereof 
27 g/kg EPA and 18 g/kg DHA. Group 2 was given high amounts of sucrose, group 3 
received glucose, group 4 fructose, group 5 amylose and group 6 amylopectin. Group 5 had to 
be given some amounts of amylopectin due to the welfare of the animals. Diets given to group 
2-6 contained the same amount of metabolizable energy (ME). The amount of ingredients in 
each diet is listed in table 2.1.  
Food intake was recorded every day and their bedding checked thoroughly for leftovers. 
Groups 2-6 were pair-fed, meaning that they all received the same amount of food every day. 
Group 1 had free access to food, but their food intake was also recorded.  
 
2.4 DATA COLLECTION 
The mice were euthanized after 9 weeks of experimental feeding. The mice were weighed 
before being gassed with the anesthetic Isofluran (Isoba-vet., Schering-Plogh, Denmark). The 
mice were anaesthetized using the apparatus Univentor 400 Anaesthesia Unit (Univentor 
Limited, Sweden), and killed by cardiac puncture.  
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Table 2.1 Ingredients in the different diets, listed as percent of weight, not percent of metabolizable 
energy (ME). 
  Low energy Sucrose Fructose Glucose Low GI High GI 
  
     
  
Protein 20 % 20 % 20 % 20 % 20 % 20 % 
Casein  20 % 20 % 20 % 20 % 20 % 20 % 
L-Cysteine 0,3 % 0,3 % 0,3 % 0,3 % 0,3 % 0,3 % 
Carbohydrate 67 % 49 % 49 % 49 % 49 % 49 % 
Corn starch 53 % 1 % 1 % 1 % 1 % 1 % 
Cellulose 5 % 5 % 5 % 5 % 5 % 5 % 
Amylose 
    
20 %   
Amylopectin 
    
14 % 34 % 
Sucrose 9 % 43 % 9 % 9 % 9 % 9 % 
Fructose 
  
34 % 
  
  
Glucose 
   
34 % 
 
  
Fat 7 % 25 % 25 % 25 % 25 % 25 % 
Soybean oil 7 % 7 % 7 % 7 % 7 % 7 % 
Fish oil   18 % 18 % 18 % 18 % 18 % 
MJ ME/kg 16,2 20,1 20,1 20,1 20,1 20,1 
Vit A (IU/kg) 4 000 4 000 4 000 4 000 4 000 4 000 
Vit D3 (IU/kg) 1 000 1 000 1 000 1 000 1 000 1 000 
Vit E (mg/kg) 75 75 75 75 75 75 
Vit K (mg/kg) 6 6 6 6 6 6 
Cu (mg/kg) 11 11 11 11 11 11 
 
2.4.1 Blood samples 
The chest of the mice was cut open and a syringe placed directly into the heart to collect 
blood. Blood samples were stored in tubes containing EDTA as anticoagulant and 
immediately centrifuged at 2500 x g and 4 °C for 5 minutes. Plasma and red blood cells were 
stored at -80 °C for subsequent analysis.  
2.4.2 Liver-, muscle- and adipose tissue 
All tissues were weighed before further treatments. Tissue samples were put in small plastic 
bags and quickly frozen, using a freeze clamp and liquid nitrogen. A small piece of the liver 
was cut off and stored for lipid analysis, the rest was to be used for RNA analysis. The tibialis 
anterior muscle was cut off from each leg. One piece was frozen as described above, the other 
was stored for lipid analysis. Three white adipose tissue depots were collected; epididymal 
(eWAT), retroperitoneal (rWAT) and inguinal (iWAT). Epididymal adipose tissue is located 
around the ureters, bladder and epididymis. The retroperitoneal fat is located around each 
MATERIALS AND METHODS 
41 
kidney. Epididymal and retroperitoneal adipose tissue are regarded as visceral fat, whereas 
inguinal fat is subcutaneous fat. Brown adipose tissue depot was also excised and weighed; 
the intrascapular brown adipose tissue (iBAT). This is located at the back of the mouse, on 
top of the shoulder blades. Fat depots were frozen as described above and stored at -80 °C for 
RNA analysis. Additionally, tissue samples from two mice in each group were collected and 
stored in 70% ethanol for histology analysis. Only eWAT was used for histology analysis.  
 
2.5 CHEMICALS AND REAGENTS 
All chemicals and reagents were purchased from commercial sources. See Appendix I for 
details.  
 
2.6 GENE EXPRESSION LEVELS  
The gene expression levels gives information on what genes are being transcribed into 
proteins. Total RNA was extracted from liver, muscle, eWAT, rWAT, iWAT and iBAT from 
each mouse. Purity and quantity of extracted RNA was measured by using Nanodrop (Saveen 
Werner, Sweden). Integrity of the RNA was measured by using Bioanalyzer (Agilent 
Technologies, USA). The RNA was then transcribed into complementary DNA (cDNA) by 
the enzyme reverse transcriptase (RT-reaction). The gene expression levels were finally 
quantified by measuring the cDNA levels by the real-time polymerase chain reaction (rt-
PCR).  
 
2.6.1 Extraction of total RNA from tissue  
Principle: Tissue samples are individually homogenized with Trizol. Chloroform is added to 
the homogenized tissue and the mix is centrifuged. The RNA is now located in the transparent 
water phase, which is transferred to another tube. Isopropanol is added to extract the RNA 
from the water phase. The enzyme DNase is used to eliminate remaining DNA.  
Procedure: 1 ml of Trizol reagent and zirconium beads were added to each tube. 50-100 mg 
frozen tissue was added to the mix and homogenized using Precellys 24 lysis & 
homogenization instrument (Bertin Technologies), at full speed for 4-6 minutes. Samples 
MATERIALS AND METHODS 
42 
were centrifuged at 12000 x g for 10 minutes at 4 °C (Eppendorf Centrifuge 5415 R), the 
supernatant extracted into new tubes and incubated at room temperature for 5 minutes. Each 
sample was added 200 µl chloroform and shaken rigorously by hand for 15 seconds. Samples 
were again incubated for 2-3 minutes at room temperature, after that they were centrifuged at 
12000 x g for 15 minutes at 4 °C. The upper layer water phase was extracted and transferred 
to new tubes. 500-750 µl isopropanol was added to each sample and mixed by turning the 
tubes upside down a few times. Samples were then incubated at room temperature for 10 
minutes, then at 4 °C for another 10 minutes. Again, they were centrifuged at 12000 x g for 
10 minutes at 4 °C. Now, the RNA was located in a pellet at the bottom of the tube. The 
supernatant was discarded using a vacuum apparatus (IBS Integra Biosciences, Vacuboy, 
Switzerland). The RNA pellet was washed with 1000-1500 µl cold 75% ethanol and vortexed 
into suspension. Samples were centrifuged at 7500 x g for 5 minutes at 4 °C. Supernatant was 
again removed by vacuum suction. The tubes with RNA pellet were incubated for 2-3 minutes 
on ice to vaporize any remaining liquid, then they were added 50-300 µl ddH2O to dissolve 
the RNA. The RNA samples were subsequently purified for any DNA residues by using the 
“DNA free kit”, according to the vendor’s description. (NIFES 2005, 281 - RNA RENSING 
OG RNA KVANTITET) 
 
2.6.2 RNA quality and quantity on the NanoDrop  
Principle: The NanoDrop ND-1000 spectrophotometer (Saveen Werner, Sweden) makes an 
accurate analysis of RNA purity and quantity, using only 1.5-2 µl of the sample. Surface 
tension is used to hold a drop of the liquid RNA in place while a measurement is made at 230 
nm, 260 nm and 280 nm.  
Procedure: A drop of RNA dissolved in ddH2O was placed on the apparatus. The 
260nm/280nm ratio and 260nm/230nm ratio were calculated. A 260nm/280nm ratio lower 
than 1.6 indicated that there were protein residues or that the RNA had not dissolved properly 
in the liquid. Protein residues may degrade the RNA. A 260nm/280nm ratio above 2.2 
indicated that there were phenol remnants in the sample. A 260nm/230nm ratio lower than 1.7 
indicates organic contaminations. Samples with nonsatisfactory ratios were precipitated with 
3M NaAc pH 5,2 and ethanol and incubated overnight at -80 °C. The samples were then 
centrifuged at 12000 x g for 10 minutes and the supernatant discarded with vacuum suction. 
The RNA was then washed with ethanol as described above, before a new measurement was 
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made on the NanoDrop.  RNA concentration between 100-3000 ng/µl is preferable. The 
NanoDrop can detect concentrations as low as 1.5 ng/µl, but the concentration has to be 
higher than 30-50 ng/µl to run qPCR. Liver has the highest concentrations of RNA, while 
adipose tissues are on the lower end of the scale. After use, the droplet of RNA was simply 
wiped off with a soft paper tissue. (NIFES 2009, NanoDrop ND-1000) 
 
2.6.3 RNA integrity on the BioAnalyzer  
Principle: RNA integrity is checked on the BioAnalyzer RNA 6000 Nano (Agilent 
Technologies) before further analysis. RNA 6000 Nano LabChip Kit (Agilent Technologies) 
contains a chip and reagents designed to determine the size of RNA fragments. Every chip 
contains microchannels which separates nucleic acid fragments by electrophoresis, based on 
the size of the fragments. The results are displayed on the program Bioanalyzer software as a 
gel-like image, electropherogram, RNA Integrity Number (RIN) and ribosomal RNA (rRNA) 
ratio (28S/18S). The peaks on the electropherogram give a visual assessment of the RNA 
quality. The RIN gives information on the degradation of RNA. A RIN-number of 1 equals 
totally degraded RNA, while a RIN-number of 10 means that the RNA is fully intact. RNA 
needs to be as intact as possible to perform qPCR, but RIN as low as 7 were accepted. The 
BioAnalyzer also calculates RNA concentration, but it is less accurate than the NanoDrop.  
Procedure: 12 samples of RNA with a concentration of 25-500 ng/µl were analyzed on the 
BioAnalyzer. A new RNA Nano chip was put in the Chip Priming station. 9 µl of gel-dye 
mixture was added to the bottom of the well in column 4, row 1, 2 and 3. 5 μl RNA 6000 
Nano Marker was added to the well with a ladder symbol and in the 12 sample wells. 1 μl 
RNA was put into the well marked with the ladder and into each of the sample wells. The chip 
was now put on the IKA vortex mixer and vortexed for 1 minute at 2400 rpm. The chip was 
now run on the BioAnalyzer. (NIFES 2006, 278 - RNA kvalitet på BioAnalyzer (RNA 6000 
Nano)) 
 
2.6.4 RT- Reaction 
Principle: Total RNA is transcribed into complementary DNA (cDNA) by the enzyme 
reverse transcriptase with access to the four deoxyNTPs. This cDNA is used to determine 
gene expression levels in subsequent qPCR analysis. One RT-plate consists of 96 wells, 
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where 18 wells must be used to calculate a standard curve and two wells must be used for 
negative controls.  
Procedure: Complementary DNA was made in duplicates from each tissue sample.  A 
standard curve with the concentrations 1000 ng/μl, 500 ng/μl, 250 ng/μl, 125 ng/μl, 63 ng/μl 
and 31 ng/μl RNA was made from a pool of RNA from all samples. This standard curve was 
included on each RT-plate in a triplicate. Due to the number of animals, 36, and the limited 
number of wells on the RT plate, 96, one RT-plate had to be made for each tissue (liver, 
muscle, eWAT, rWAT, iWAT and iBAT). Two negative controls were included into each 
RT-plate, one “non amplification control” and one “non template control”. 50 μl cDNA was 
made from the liver-RNA due to the high number of hepatic genes we wanted to run, while it 
was sufficient to make 30 μl cDNA for the other 5 tissues. The reagents used for both 
volumes are listed in table 2.2. 20 or 40 μl of this mix was added to each of the 96 wells on 
the RT-plate. 40 μl of the mixture was used for liver RNA and 20 μl mixture for all other 
tissues. 10 μl RNA was added to each well, except for the non template control. All RNA, 
except for RNA used for the standard curve, had a concentration of 50 (liver RNA) or 30 
ng/μl (other tissues). 
 
Table 2.2 Reagents for 30 μl and 50 μl RT-reaction. 
  Reagents 30μl 50μl 
Final 
concentration 
Non enzymatic 
reagents 
H2O free from RNase 1,3 8,9   
10X TaqMan RT buffer 3 5 1X 
25 mM MgC l2 6,6 11 5.5 mM 
10mM deoxyNTPs Mixture (2.5 mM of each 
dNTP) 6 10 
500 μM per 
dNTP 
50 μM Random hexamers/oligo d(T)16 1,5 2,5 2.5 μM 
Enzymes RNase Inhibitor (20U/μl) 0,6 1 0.4 U/μl 
Multiscribe Reverse Transcriptase (50U/μl) 1 1,67 1.67 U/μl 
 
A cover was put on the RT plate before centrifugation at 50 x g for 1 minute (Eppendorf 
Centrifuge 5810 R). The plate was then run through thermal cycling on the Gene Amp PCR 
Systems 9700 PCR machine. The thermal cycles for the reaction are shown in table 2.3. After 
synthesis, the cDNA was stored at -20 °C until qPCR analysis. (NIFES 2009, 279 RT-
reaction) 
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Table 2.3 Reverse Transcriptase reaction, thermal cycling 
Step Incubation RT 
Reverse Transcription 
Inactivation End 
 
    
Temperature (ºC) 25 48 95 4 
Time(minutes) 10 60 5 ∞ 
Volume (μl) 50 or 30 
 
2.6.5 Quantitative Real-Time PCR 
Principle: Gene expression levels in the different tissues are determined by quantitative real-
time polymerase chain reaction (qPCR). Sequence-specific primers bind to the cDNA made in 
the RT-reaction, amplifying the gene of interest. The amplification follows three steps:  
1. Denaturation of DNA at 95°C: High temperature melts double-stranded DNA 
(dsDNA) into single-stranded DNA (ssDNA), without destroying it. 
2. Annealing at 60°C: The primers of the gene of interest binds to complementary 
ssDNA. 
3. Extension at 72°C: The primers bound to complementary ssDNA are extended, 
making a copy of the gene of interest.  
The amplification is exponential, meaning that the number of cDNA copies is multiplied by 
two for each thermal cycle. This amplification can be followed by fluorescence, due to DNA-
binding dye added to the reaction. The more a gene is expressed in the tissue, the faster it will 
accumulate in a qPCR reaction.  The dye used in this reaction is SYBR GREEN, which binds 
to all double-stranded DNA (dsDNA) in a PCR reaction. Upon binding to dsDNA, SYBR 
GREEN emits a strong fluorescent signal. The point when the fluorescence from the dsDNA-
SYBR GREEN complex is significantly greater than the background fluorescence is called 
the threshold level. This measures the amount of PCR product when the reaction is still in the 
exponential phase and it is only at the exponential phase it is possible to determine the starting 
amount of the cDNA. The fractional number of PCR cycles required to reach the threshold 
level is proportionate to the starting amount of cDNA in the sample. This value is called the 
cycle threshold (CT) value. (Ginzinger 2002) An example of a qPCR reaction is illustrated in 
figure 2.2.  
The sequences of the primers used can be found in Appendix II. 
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Figure 2.2 Amplification plot of a hypothetical quantitative real-time PCR reaction. The amplification 
plot is the plot of the fluorescent signal vs PCR cycle numbers. The signal from the dsDNA-SYBR 
GREEN complex is accumulating during the baseline phase, but it is beneath the detection limit of the 
instrument. The signal measured during the baseline PCR cycles is used to plot the threshold level. 
The threshold level is calculated as 10 x the standard deviation of the average baseline fluorescent 
signal. A fluorescent signal above the threshold level is used to define the CT value for the sample. 
The CT is the fractional number of PCR cycles required to reach the threshold level. The CT values for 
different samples are then compared to calculate the relative abundance of starting cDNA for each 
sample. The CT values for this plot is 18 for the solid line and 20 for the dotted line. There is a 
difference of two cycles between these samples, which due to the exponential amplification of the 
PCR reaction means that there was four times as much cDNA in the sample represented by the solid 
line compared to the sample represented by the dotted line. (Ginzinger 2002) 
The gene expression levels were normalized to the relative expression of housekeeping genes. 
Housekeeping genes are expressed at relatively stable levels and are required for basic cellular 
functions, and should not be affected by experimental treatment. β-actin, TATA box binding 
protein (TBP) and calnexin were tested as housekeeping genes. After evaluation by geNorm, 
TBP was selected as the best normalizing gene (described below). 
Procedure: Reaction mix was made of the reagents listed in table 2.4. This mix is sufficient 
for measuring one gene in four cDNA plates or four genes in one cDNA plate. 18 μl of the 
reaction mix along with 2 μl cDNA was transferred to each well in a 384-well reaction plate, 
using BioMek 3000 Laboratory Automation Workstation (Beckman Coulter, USA). That 
added up to a total of 20 μl reagent mix in each well.  
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Table 2.4: SYBR GREEN reaction mixture for a 384-well reaction plate. 
Reagent Volume (μl) 
ddH2O 290 
Primer forward (100μM) 5 
Primer reverse (100μM) 5 
SYBR GREEN Master Mix 500 
 
qPCR amplification of the target genes was performed on Light Cycler 480 Real-Time PCR 
System (Roche, Norway). First, there was an initial step of denaturation at 95 °C for 5 
minutes, followed by 45 thermal cycles. These thermal cycles were each of 10 seconds of 
denaturation at 95 °C, 20 seconds of annealing at 60 °C, and 30 seconds of extension at 72 °C. 
The reaction is listed in table 2.5. (NIFES 2005, 280 RealTime PCR) 
Table 2.5: The SYBR GREEN program on Light Cycler 480 
Step Preincubating Amplification Melting point analysis Cooling 
Temperature (ºC) 95 95 - 60 - 72 95 - 65 - 97 40 
Time 5m 10s - 20s - 30s 5s - 1m -  10s 
Number of cycles 1 45 1 1 
Volume (μl) 20 
 
All samples were run in duplicates, whereas the standard curve was run in triplicates. The 
LightCyclers software program (LightCycler 480 Software release 1.5.0 SP4) draws graphs of 
the amplification curves. The curves of two duplicates or three triplicates were checked to 
verify that they matched. The program calculates the CT value, efficiency value and error, 
based on the standard curve. An efficiency value of 2 is optimal, but between 1.8 and 2.2 is 
acceptable. An error value less than 0.04 was accepted in this study.  
 
2.6.6 Calculating the relative gene expression in geNorm 
Principle: geNorm is a software program used to calculate relative gene expression based on 
the CT-values from the qPCR and normalize the expression relative to the expression of 
housekeeping genes. Housekeeping genes are transcribed into proteins that are necessary for 
basic cellular functions and are not expected to change by feeding the animals different diets. 
The housekeeping genes are used to calculate a normalization factor, which normalizes the 
expression of the target gene CT-values. This excludes variables that could have an effect of 
the cDNA synthesis, such as differences in starting material or enzymatic reaction rates.  
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Procedure: The CT-values of the all genes are first transferred to an Excel-sheet which gives 
the highest CT-value a quantity of 1. The other CT-values are given quantities lower than one, 
based on their CT-value relative to the highest CT-value. All quantities of the housekeeping 
genes are then copied into the geNorm program. This program calculates which of the 
housekeeping genes are better for normalization, or it uses a combination of several 
housekeeping genes. This gives a normalization factor for each tissue sample. TBP proved to 
be the best housekeeping gene. This has also been used in previous studies (Madsen et al 
2008). The relative gene expression is the end result of the RNA extraction and is used to 
calculate statistics and draw graphs. The relative gene expression for each gene in each tissue 
sample is calculated in by the formula: 
Relative gene expression = Quantity of the gene/ Normalization factor of the sample 
 
2.7 HISTOLOGY 
In order to examine obesity development and morphological structures of the adipose tissue, 
histological methods were used to examine the tissue under a microscope. Tissues were 
fixated in formaldehyde, dehydrated by ethanol, cleared by xylene and embedded in paraffin. 
The tissue in the paraffin block was cut into slides and stained by hematoxilin and eosin. The 
cells were now visible in a microscope.  
2.7.1 Fixation and dehydration  
Principle: Fixation in formaldehyde is used to protect the tissue against bacteria and 
enzymatic degradation. This preserves the structure of the tissue for later examination.  
Procedure: After termination of the mice, the different tissues were fixed in 4% 
formaldehyde. After 24 hours, the tissues were washed with a 0.1 M phosphate buffer 
adjusted to pH 7.4. The phosphate buffer was then replaced by 50% ethanol and placed in a 
mixing machine (HS 501 D, JANKE & KUNKEL, IKA ® Labortechnik, Germany) for 1 
hour. The ethanol was replaced and the process repeated three times. Finally, the 50% ethanol 
was replaced by 70% ethanol and stored at 4 °C. (NIFES 2009, 28 – UTTAK AV PRØVER 
TIL HISTOLOGI-ANALYSER) 
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2.7.2 Dehydration and clearing  
Principle: The tissues are to be embedded in paraffin, but paraffin is not soluble in water. The 
water from the tissues is removed by placing them in different baths of ethanol with 
concentrations increasing from 70% to 100% ethanol. Then the tissues are made transparent 
by xylene and placed in liquid paraffin. 
Procedure: Tissue samples of eWAT were placed in different solutions of ethanol, xylene 
and paraffin. When the ethanol was replaced by xylene, the tissues were kept in a fume hood. 
The tissues remained in xylene until they became transparent, before they were transferred 
into cassettes and placed in liquid paraffin. The procedure was performed twice, on two 
different sets of samples, with some variations in the protocol steps. The procedures are listed 
in tables 2.6 and 2.7. (NIFES 2010, Retningslinjer for bruk av histologilaboratoriet) 
Table 2.6 First attempt at dehydration of the tissues 
Step Solution Time 
1 70% ethanol 30 minutes 
2 96% ethanol 1-2 hours 
3 96% ethanol over night 
4 100% ethanol 30 minutes 
5 100% ethanol  until end of day 
6 100% ethanol over night 
7 100% ethanol + a drop of eosin 1 hour 
8 50/50 xylene and 100% ethanol 30 minutes 
9 xylene 1-5 minutes 
10 liquid paraffin 3 hours 
11 liquid paraffin 3 hours 
12 solid paraffin over night 
 
Table 2.7 Second attempt at dehydration of the tissues 
Step Solution Time 
1 75% ethanol 30 minutes 
2 96% ethanol 75 minutes 
3 96% ethanol 75 minutes 
4 100% ethanol 60 minutes 
5 100% ethanol  60 minutes 
6 xylene 60 minutes 
7 xylene 60 minutes 
8 liquid paraffin overnight 
9 liquid paraffin 3 hours 
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2.7.3 Paraffin embedding and sectioning 
Principle: To obtain sections of tissues thin enough to be studied in the microscope, tissues 
are embedded in paraffin. Cold paraffin blocks are then cut into 4 μm slides, containing cells 
in their original structure from that particular part of the tissue. The tissue sections are then 
transferred to glass slides.  
Procedure: The tissue samples in their respective cassettes were transferred into a paraffin 
bath on the EC 350 Paraffin Embedding Center (Microm International, Waldorf, Germany). 
Each sample was placed in a steel tray which was partly filled with liquid paraffin. The 
bottom part of the cassette was placed on top of the steel tray and it was completely filled 
with liquid paraffin. The paraffin was hardened at 4 °C for at least 24 hours, until sectioning. 
Sectioning was performed on a manual microtome (Leica RM2165, Germany). 4 μm sections 
of the paraffin embedded tissue was cut off and transferred to a bowl of 50/50 ddH2O and 
methanol. This bowl held a temperature of approximately 45 °C, due to its placement on a 
heater (Slide Warmer SW85, Adamas Instrumenten BV, Netherlands). The warm water and 
methanol made the sections stretch out before they were transferred to glass slides. The slides 
were left to dry in room temperature and then placed in a box for subsequent staining. (NIFES 
2010, Retningslinjer for bruk av histologilaboratoriet) 
 
2.7.4 Staining of the tissue with hematoxylin and eosin 
Principle: The tissues are stained in order to examine the cells under a microscope. 
Hematoxylin colors the nuclei of the cells dark blue, eosin colors the cytoplasm pink. This 
makes it possible to differentiate cell types and determine cell size. The tissues are first 
rehydrated with water before staining. After staining with both colorants, the tissues are 
dehydrated with ethanol and xylene before they are sealed with mounting medium under and 
a thin glass slide.  
Procedure: The tissue slides were put into racks which were placed in a number of glass 
baths. These glass baths were filled with the liquids listed in table 2.8. The time the rack spent 
in each bath is also listed in table 2.8. After the staining process, the slides were mounted with 
the xylene-based Entellan mounting medium (Merck, Germany) and a thin glass slide was 
placed on top. Weighs were used to spread the mounting medium evenly over the tissue 
section. (NIFES 2010, Retningslinjer for bruk av histologilaboratoriet) 
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Table 2.8 Dying paraffin sections with hematoxylin and eosin 
Step  Solution Time 
1 Xylene 5 min 
2 Xylene 5 min 
3 100% ethanol 5 min 
4 100% ethanol 5 min 
5 96% ethanol 5 min  
6 96% ethanol 5 min 
7 70% ethanol 5 min 
8 50% ethanol 5 min 
9 ddH2O 5 min 
10 Hematoxylin 3 min 
11 warm tap water (45°C) 5 min 
12 ddH2O Rinse 
13 96% ethanol 10 dips 
14 Eosin 30 sec 
15 96% ethanol Rinse 
16 96% ethanol 5 min  
17 96% ethanol 5 min 
18 100% ethanol 5 min 
19 100% ethanol 5 min 
20 Xylene 5 min 
21 Xylene 5 min 
Mount with Entellan 
 
2.7.5 Microscopy 
The slides of adipose tissue were visually examined on a binocular microscope, (Olympus BX 
51, System microscope, Japan). The slides were viewed at 100X and 400X magnifications. 
Pictures were taken using a Nikon DS-Fi1 camera (Nikon Corporation, Japan).  The pictures 
were displayed by the software program NIS Elements F 3.0 (Nikon Corporation, Japan).  
 
2.8 PLASMA ANALYSES 
Plasma was analyzed for insulin levels, glucose, non-esterified fatty acids (NEFAs), 
triacylglycerols (TAGs), glycerol, D-3-hydroxybutyrate, alanine aminotransferase (ALT) and 
lactate dehydrogenase (LDH). 
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2.8.1 Insulin levels in plasma by ELISA-kit 
Principle: Insulin is the primary hormone responsible for control of the glucose metabolism. 
Insulin levels are raised in mice suffering from Type 2 diabetes and obesity. The Insulin 
(Mouse) UltraSensitive ELISA-kit (DRG Instruments gmbH, Germany) was used to measure 
insulin levels in the plasma of each mouse. ELISA is the abbreviation for solid phase enzyme-
linked immunosorbent assay. 96 wells are coated with a monoclonal antibody directed 
towards an antigenic area on the insulin molecule. The plasma samples are placed in the wells 
with enzyme conjugate, which is an anti-insulin antibody bound to biotin.  This binds to the 
insulin in the sample. During the second step, streptavidin peroxidase enzyme complex binds 
to the biotin in the first conjugate. The amount of this complex, which is measured in its 
intensity of color developed by the reaction with 3,3’-5,5’-tetramethylbenzidine, is 
proportional to the concentration of insulin in the sample. The enzymatic reactions are 
proportional to incubation time and temperature, therefore it is important that all samples are 
treated equally and the test is run through all steps without delay.  
Procedure: The kit was brought to room temperature before use. Standards and samples were 
run in duplicates. 25 μl of standard 0 from the kit was added to each of the 96 wells. 5 μl of 
standard 0 and 3-7 was added to each of the standard wells. 5 μl sample plasma was added to 
each sample well. 50 μl enzyme conjugate was dispensed into each well. This was thoroughly 
mixed, without foaming the liquids, on a shaker at 800 x g for 2 hours at room temperature. 
After incubation, the plate was rinsed 6 times with an automatic plate washer (Skan Washer 
300 version B, Skatron Instruments, Lier, Norway) and the liquid was briskly discarded out of 
the wells onto absorbent paper. 200 μl of TMB solution from the kit was added to each well 
before incubation for 30 minutes. Then 50 μl of Stop solution from the kit was added to each 
well. The plate was shaken for 10 seconds at 800 x g and then immediately read by a 
microtiter plate reader (iEMS Reader MF, Labsystems Oy, Helsinki, Finland). The 
absorbance was measured at 450 nm and 620 nm. (User manual, Insulin (Mouse) 
UltraSensitive ELISA, DRG Diagnostics) 
2.8.2 MAXMAT analysis 
Plasma levels of glucose, NEFAs, TAGs, glycerol, D-3-Hydroxybutyrat, ALT and LDH were 
measured on an automatic multi-purpose analyzer (MAXMAT) by laboratory technician 
Jacob Wessels at NIFES.  
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2.8.3 Lipids in muscle and liver by thin layer chromatography  
Analysis of cholesterol levels of muscle tissue and amount of total lipids in liver was 
measured by laboratory technician Jan Idar Hjelle at NIFES. This was done by thin layer 
chromatography (TLC) on a silica gel. (NIFES 2008, 375 – Fettsyresammensetning av 
totalfettsyrer i ulike lipidklasser) 
 
2.9 SOFTWARE USED FOR STATISTICAL ANALYSIS 
Statistical analysis was performed to find any significant differences between groups. All 
results are presented as the mean +/- standard error (SEM) of the mean for each group.  The 
SEM gives an indication of how close the sample mean is likely to be to the mean of a whole 
population. The SEM is calculated from the standard deviation, divided by the square root of 
the number of animals: 
    
                  
  
 
 
All information on samples, analysis and results were stored on Labware LIMS. 
The geNorm algorithm was used to assess the stability of the housekeeping genes. 
Microsoft Excel was used to calculate means, standard deviations and standard error of the 
mean. 
Statistica was used to test the results for significant differences between groups. The Sugar 
groups and GI groups were tested separately, both included the Chow control group. Levene’s 
test was performed to test the equality of variances in each group. If the samples did not have 
equal variance, the values were log transformed and tested again. Data which did not have 
equal variance were tested by the Kruskal-Wallis non-parametric test for significant 
differences. Normally distributed data were tested with one-way analysis of variance and 
Fisher’s exact test. P-values less than 0.05 were considered as significant difference.  
All graphs were made on GraphPad Prism 5.  
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3. RESULTS – SUGAR GROUPS 
The aim of this study was to investigate whether the anti obesity effect of fish oil is attenuated 
by sucrose. Also, we wanted to investigate whether the possible obesogenic effects derived 
from the glucose moiety in the sucrose molecule, the fructose moiety, or both.  
The mice were pair-fed high fat diets containing fish oil + sucrose, fish oil + glucose or fish 
oil + fructose. Standard low fat chow diet was given to the control group. The compositions of 
the diets can be seen in table 2.1, page 40 of Materials and methods. From now on the 
different diet groups will be labeled chow, sucrose, glucose and fructose. Any significant 
differences will be marked by different letters on the graphs.  
This study was performed parallel to the study of different starches in combination with fish 
oil. The results of that study are described at page 71-85, section 4. 
 
3.1 FOOD INTAKE, BODY WEIGHT DEVELOPMENT AND FEED EFFICENCY 
The mice were fed the experimental diets for 9 weeks. The chow group was given food ad 
libitum, whereas the other groups were restricted in their food intake. The chow feed 
contained lesser calories per gram than the other feeds, so these mice ate more food measured 
in grams than the other groups (not shown). The accumulated calories ingested, the weight 
gain and the energy efficiency is shown in Figure 3.1A-C. The body weight development is 
shown in figure 3.1D. 
All pair-fed groups ate of course the same amount of calories, and luck would have it that the 
chow group also ate the same as the other groups, when adjusted for calories (Fig 3.1A). After 
9 weeks of feeding, the mice where weighed before termination. The total weight gain in 
grams is shown in figure 3.1B. Mice on fish oil diets gained less weight than mice on chow 
diet and the difference is statistically significant for the fructose group. The energy efficiency 
is shown in figure 3.1C. All mice on fish oil diets showed a tendency towards lower weight 
gain compared to the chow group. Mice with fructose as their main carbohydrate source 
gained significantly less weight per calorie ingested than mice on chow and glucose diet. The 
mice were weighed twice a week. The body weight development is shown in figure 3.1D. 
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There was a drop in the weight development some days before termination due to changes in 
the mice’s environment, but it does not seem to have affected the end result.  
 
Figure 3.1: Feed intake and body weight development of the C57BL/6J mice. Total calories ingested 
(A), total weight gain from start to end of the experiment (B), weight gain (g) per calorie ingested (C) 
and Body weight development during the experiment. Groups marked by different letters are 
significantly different. 
 
3.2 ORGAN WEIGHTS 
Figure 3.2A shows the end mean body weights of the groups. After termination, organ 
weights were recorded. We selected the retroperitoneal adipose tissue (rWAT, Fig 3.2B), 
epididymal adipose tissue (eWAT, Fig 3.2C), inguinal adipose tissue (iWAT, Fig 3.2D), 
intrascapular brown adipose tissue (iBAT, Fig 3.2E), tibialis muscle (Fig 3.2F) and liver (Fig 
3.2G). 
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Figure 3.2: Total body weight (A), rWAT weight (B), eWAT weight (C), iWAT weight (D), iBAT weight 
(E), tibialis weight (F) and liver weight (G). All weights are displayed in grams. Groups marked by 
different letters are significantly different.  
Although the weight gain varied significantly (Fig 3.1B), the total body weights at the end of 
the experiment did not (Fig 3.2A). Still, the organ weights varied, especially within the 
adipose tissue depots. The sucrose group showed a tendency towards having more visceral fat, 
and the glucose group had slightly more subcutaneous fat. Whereas white adipose tissue 
mainly stores energy, brown adipose tissue is also capable of burning energy. The chow group 
had the largest depots of brown fat, which is considered a healthier type of fat capable of 
turning stored fat into heat to regulate body temperature (Gesta et al 2007). It is to be noted 
that the chow group, who ended up as slightly heavier than the other groups, did not have the 
largest white adipose tissue depots. The smaller mice in the fructose group continuously had 
the smallest adipose tissue depots.  
Retroperitoneal white adipose tissue (rWAT) weights are shown in figure 3.2B. This is a 
visceral fat depot and the sucrose group had the largest amounts of it, even though the chow 
group had gained somewhat more weight during the experiment (Fig 3.1B). The difference 
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was only statistically significant for the fructose group, which had the smallest amounts of 
rWAT. The sucrose group also had slightly more epididymal white adipose tissue (eWAT) 
(Fig 3.2C), which is also a visceral fat depot. The fructose group had significantly smaller 
eWAT depots compared to sucrose and chow groups. Inguinal white adipose tissue (iWAT) is 
a subcutaneous fat depot. Here, the glucose group had the largest amounts, second only to the 
sucrose group (Fig 3.2D). Both had significantly larger iWAT depots compared to the 
fructose group, whereas the chow group fell somewhere in the middle.  
Intrascapular brown adipose tissue (iBAT) depots were larger in the chow fed mice. They 
were significantly larger compared to the fructose fed mice (Fig 3.2E). The trend seems to be 
that the mice who gained the most weight had the largest amounts of iBAT. This trend is also 
seen in the comparisons of the tibialis weights (Fig 3.2F), which is a muscle located at the 
hind leg of the mouse. Although not significantly smaller in body weight, the mice fed 
fructose had significantly smaller tibialis compared to the chow fed mice. Liver weights were 
not significantly different between groups (Fig 3.2G).  
 
3.3 HEPATIC GENE EXPRESSION 
A great number of genes were measured in the liver to elucidate potential differences in 
metabolisms between groups. The liver is capable of both lipid synthesis and breakdown, as 
well as glucose and amino acid metabolism. All genes measured were normalized to the 
housekeeping gene TBP. 
Lipogenic gene expression 
The relative expression levels of lipogenic genes are shown in figure 3.3. Lipogenic genes are 
genes coding for proteins associated with the de novo synthesis of fatty acids. They are 
expressed when food is at a surplus and the body has the opportunity to store excess calories. 
We measured the relative expressions of Srebp1c, Acc1, Acc2, Scd1, Fas and Dgat. The 
function and regulation of these genes are described at page 21-25 of the Introduction.  
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Figure 3.3: The relative expression levels of hepatic Srebp1c (A), Acc1 (B), Acc2 (C), Scd1 (D), Fas 
(E) and Dgat (F) mRNA. Groups marked by different letters are significantly different.  
The expression of the transcription factor Srebp1c was significantly higher in the fructose 
group, compared to the chow and glucose group (Fig 3.3A). Fructose consumption has been 
shown to lead to overexpression of Srebp1c, although the link between fructose and Srebp1c 
is less prominent in C57BL/6J mice (Nagata et al 2004). Therefore it is surprising to find that 
the fructose group had the highest level of Srebp1c, since insulin caused by sucrose 
consumption is also known to increase Srebp1c expression rates (Osborne 2000). The effect 
of PUFAs did not seem to protect the sugar-fed mice against high Srebp1c expression rates, 
since none of the groups given fish oil have significantly lower expression levels compared to 
the chow group. The glucose group had the lowest level of Acc1 mRNA, significantly lower 
than the chow group (Fig 3.3B). Acc1 is partly controlled by the transcription factor Srebp1c 
(Kim 1997), but there seems to be no correlation between the expressions of these two genes. 
Other factors, such as posttranslational modifications of SREBP-1c, must be affecting the 
expression of lipogenic genes. A low-fat, carbohydrate-rich diet can up-regulate the 
expression of both Accs and Fas (Ishii et al 2004). The trend is that the chow group has the 
highest expression rates of Acc1, Acc2, Fas and Scd1 (Fig 3.3B-E). The difference does not 
reach statistical significance for all values, but it is previously shown that PUFAs are 
inhibitors of Scd1 (Ntambi 1999) and Fas (Ren et al 1997). Dgat expression was not affected 
by the different diets (Fig 3.3F).  
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Genes increasing fatty acid breakdown 
The relative expression levels of genes which increases fatty acid breakdown are shown in 
figure 3.4. These genes code for enzymes involved in breaking down fatty acids to satisfy 
energy demands. We measured the expression levels of Pparα, Pparδ, Aco, Cpt1a, Cpt2 and 
Hmgcs2. The function and regulation of these genes are described at page 25-28 of the 
Introduction.  
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Figure 3.4: Relative expression levels of the genes Pparα (A), Pparδ (B), Cpt1a (C), Cpt2 (D), 
Hmgcs2 (E) and Aco (F) in liver. Groups marked by different letters are significantly different.  
There were no significant differences in the expressions of Pparα, Pparδ, Cpt1a or Hmgcs2 
(Fig 3.4A, B, C and E). Cpt2-expressions in sucrose and glucose-groups were significantly 
higher than the Cpt2 levels in chow-group (Fig 3.4D), but as described in the introduction, 
this is not a rate-limiting enzyme. The Aco gene, coding for the peroxisomal enzyme Acyl-
CoA oxidase, was significantly up-regulated in the glucose-group, compared to the chow-
group (Fig 3.4F). It also seems to be up-regulated in the sugar and fructose-groups, although 
the standard error is high.  
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Gluconeogenesis 
The relative expression levels of genes involved in gluconeogenesis are shown in figure 3.5. 
The function and regulation of these genes are described at page 28 of the Introduction. 
Gluconeogenesis is the making of new glucose during fasting. Patients with Type 2 diabetes 
have elevated blood glucose levels during fasting, due to high gluconeogenesis. PCK1 is the 
rate-limiting enzyme during gluconeogenesis and PGC-1α is a coactivator of PCK1.  
 
Figure 3.5: Relative expressions of the gluconeogenetic enzymes Pgc1α (A) and Pck1 (B) in liver. 
Groups marked by different letters are significantly different.  
As seen in figure 3.5, mice given fish oil and sugars did not have elevated levels of Pgc1α 
compared to the chow group (Fig 3.5A). Mice given glucose even had significantly lower 
levels of Pgc1α compared to the chow group. The levels of Pck1 showed no significant 
differences, although some of the mice in the fructose group had elevated levels of this 
mRNA (Fig 3.5B).  
 
Amino acid degradation 
The relative expression levels of genes involved in amino acid degradation are shown in 
figure 3.6. Amino acids can be turned into glucose molecules when there is a shortage of 
glucose. Glucose is required as energy for the brain and red blood cells. We measured the 
expressions of Agxt, Got, Gpt1 and Cps1. The enzyme products of these genes are described 
at page 29 of the Introduction.  
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Figure 3.6: The relative expressions of mRNA coding for hepatic enzymes involved in amino acid 
degradation. Agxt (A), Got (B), Gpt1 (C) and Cps1 (D) were measured. Groups marked by different 
letters are significantly different.  
Only Agxt showed significant differences (Fig 3.6A). It seems that amino acid degradation is 
more or less the same for mitochondrial enzymes, whereas the peroxisomal enzyme Agxt is 
up-regulated in the chow group compared to all fish oil groups. 
 
Cyclic AMP signaling 
The relative expression levels of genes involved cyclic AMP (cAMP) signaling are shown in 
figure 3.7. cAMP is an intracellular second messenger which induces gluconeogenesis in the 
liver. CREM and the cAMP-dependent protein kinase (PKA) isoforms RIα and RIIβ are 
enzymes in the cAMP signaling pathway. PDE4c is an enzyme which degrades cAMP. Low 
level of Pde4c is linked to an anti-inflammatory state. These genes are described at page 30-
31 of the Introduction. 
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Figure 3.7: cAMP signaling. The relative expressions of RIα (A), RIIβ (B), Crem (D) and Pde4c (E). 
Figure 7C shows the RIα: RIIβ-ratio. Groups marked by different letters are significantly different.  
As seen from the graph, there were no significant differences in the RIα and RIIβ expression 
levels (Fig 3.7A and B). The RIα: RIIβ ratios were a little lower for the fish oil groups 
compared to the chow group, but differences were not statistically significant (Fig 3.7C). The 
level of Crem was significantly lower in the fructose group, compared to the chow group (Fig 
3.7D). The levels of Crem in sucrose and glucose group were also lower, but the values did 
not reach statistical significance. The levels of Pde4c were not very different, but there might 
be a trend towards a slight reduction in the fish oil groups (Fig 3.7E).  
 
3.4 GENE EXPRESSIONS IN WHITE ADIPOSE TISSUE 
Expressions of genes involved in adipogenesis, inflammation and genes that give white 
adipocytes a brown-like phenotype were measured in white adipose tissue. All genes 
measured were normalized to the housekeeping gene TBP. 
Adipogenesis  
The relative mRNA expressions of the lipogenic transcription factors PPARγ2 and SREBP-1c 
were measured, along with the expressions of the lipogenic enzyme FAS (Fig 3.8). These 
enzymes are described at page 21-25 of the Introduction. Two different fat depots were 
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analyzed, eWAT and iWAT. eWAT is a visceral fat depot, whereas iWAT is a subcutaneous 
fat depot.  
 
Figure 3.8: Relative expressions of adipogenic genes in white adipose tissue:  Pparγ2 (A and B), 
Srebp1c (C and D) and Fas (E and F). Measurements from epididymal fat to the left and inguinal fat to 
the right.  
Differences in the levels of Pparγ2, Srebp1c and Fas did not reach significant differences (Fig 
3.8A-F). The levels in eWAT were about the same between groups, whereas the levels in 
iWAT were more diverged. The standard errors were too high to claim anything with 
certainty, but the trend seems to be that the lipogenic genes in iWAT are expressed at higher 
levels in the chow and fructose group. The mRNA expression levels of the transcription factor 
PPARγ2 and SREBP-1c is not necessary the best indicator for the level of active PPARγ2 and 
SREBP-1c enzymes in the cells, as both enzymes have to be activated posttranslationally 
before functioning as transcription factors.  
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Inflammation markers 
The expression levels of the inflammation markers Ccl2, Cd68, Emr1 and Serpine1 were 
measured in both epididymal and inguinal white adipose tissue. These genes are involved in 
macrophage accumulation and are described at page 31-34 of the Introduction. The results of 
Serpine1 are not shown due to high standard errors of the mean. The rest of the results are 
shown in figure 3.9. 
 
Figure 3.9: Relative expression levels of inflammatory genes in white adipose tissue:  Ccl2 (A and B), 
Cd68 (C and D) and Emr1 (E and F). Measurements from epididymal fat to the left and inguinal fat to 
the right. Groups marked by different letters are significantly different. 
As seen from the figure, the expression levels in the visceral epididymal fat exhibits a clear 
trend for the three genes measured. Visceral fat is known to exhibit more inflammatory 
markers compared to subcutaneous fat (Ouchi et al 2011). The expression levels of 
inflammatory markers in epididymal WAT were higher in the sucrose group for all genes 
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measured. The differences reach statistical significance compared to fructose group for Ccl2, 
Cd68 and Emr1. The differences were not significant for Serpine1, but the trend of the 
sucrose group to have the highest level is still there (not shown). It must be noted that the 
mRNA levels are measured as concentration levels, and sucrose group had the highest 
amounts of visceral fat, which dramatically increases the burden of inflammation compared to 
the fructose group. The fructose group had lower concentrations of inflammatory markers and 
also smaller visceral adipose tissues, so the total burden of inflammation is probably distinctly 
lower in this group. 
The results for the subcutaneous inguinal WAT do not show any significant differences, and 
there is less consistency between expression levels of the different inflammation markers. 
There is a trend towards glucose having higher levels of inflammatory markers. This makes 
sense considering that this group had the largest iWAT depots (Fig 3.2D). There is a 
correlation between large adipose mass and high inflammation, although the causal 
relationship between these two factors are not fully understood.  
 
Brown-like phenotype of WAT 
We measured the expression levels of Pgc1α and Ucp1 in both epididymal and inguinal fat 
depots. Unfortunately, the results from Ucp1 showed high variance within groups, indicating 
that something had gone wrong with this the measurement of this gene. The results of Ucp1 
levels are therefore not shown, but the expression level of Pgc1α is found in figure 3.10. The 
function of PGC-1α in adipose tissue can be found at page 35 of the Introduction.  
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Figure 3.10: The relative expression levels of Pgc1α in epididymal (A) and inguinal (B) fat.  
No significant differences were reached, but there seems to be a trend towards fish oil groups 
having higher levels of Pgc1α in visceral fat. This might be considered as a positive effect of 
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fish oil, since visceral fat is regarded as the more unhealthy type of fat. Increasing the brown-
like phenotypes in visceral fat could improve the metabolic status of this adipose tissue. 
Within the fish oil groups, fructose has the highest level of Pgc1α in eWAT and sucrose 
group has the lowest.  
In contrast, the fish oil groups seem to have lower values of Pgc1α in subcutaneous fat 
compared to chow group.  
 
3.5 GENE EXPRESSION LEVELS IN BROWN ADIPOSE TISSUE 
In intrascapular brown adipose tissue, Pgc1α, Dio2 and Ucp1 were measured to examine 
differences in adipocyte phenotypes. Unfortunately, for reasons described above, Ucp1 results 
are not shown. The expression levels of Cox2 were determined as a measurement of 
mitochondrial function. The expressions of the lipogenic genes Srebp1c and Rip140 were also 
measured in BAT. The enzyme products of these genes are described at page 34-36 of the 
Introduction. All genes measured were normalized to the housekeeping gene TBP. The results 
are displayed in figure 3.11. 
11A - Pgc1a
R
e
la
ti
v
e
 e
xp
re
s
s
io
n
0
2
4
6
8
10
a
a
a
b
11B - Dio2
0
5
10
15
20
25
a
ab
ab
b
11C - Cox2
R
e
la
ti
v
e
 e
xp
re
s
s
io
n
0
5
10
15
ab ab
a
b
11D - Srebp1c
R
e
la
ti
v
e
 e
xp
re
s
s
io
n
C
ho
w
Su
cr
os
e
G
lu
co
se
Fr
uc
to
se
0
5
10
15
20
a
b
a
ab
11E - Rip140
C
ho
w
Su
cr
os
e
G
lu
co
se
Fr
uc
to
se
0
1
2
3
4
Brown adipocyte phenotype
Mitochondrial function
Brown adipocyte lipogenesis
iBAT
 
RESULTS – SUGAR GROUPS 
67 
Figure 3.11: The expression levels of genes involved in adipocyte phenotype, mitochondrial function 
and lipogenesis in BAT. Pgc1α (A), Dio2 (B), Cox2 (C), Srebp1c (D) and Rip140 (E). Groups marked 
by different letters are significantly different. 
As seen from the figure, the fructose group had significantly higher expression levels of the 
BAT-specific genes Pgc1α (Fig 3.11A) and Dio2 (Fig 3.11B). This indicates that the fructose 
group has a higher capacity of turning fat into heat, which would explain why these mice are 
leaner than the other groups. They also have higher expression levels of Cox2 (Fig 3.11C), 
which is consistent with the hypothesis of the fructose mice having higher capacity of burning 
fat.  
The expression of lipogenic genes is less consistent. Fructose group have lower expression 
levels of Srebp1c compared to chow and glucose group, but the difference does not reach 
statistical significance. Surprisingly, sucrose group had the lowest levels of Srebp1c. The 
results from Rip140 expression levels indicate a slight increase in the fish oil groups 
compared to chow group. This is not consistent with the fact that chow and sucrose group had 
the highest body weights and the largest fat depots. These results combined with the results 
from lipogenic expression levels in liver and white adipose tissue indicates that the expression 
levels of lipogenic genes are not rate-limiting for the capacity of accumulating fat. Activation 
and repression of translation of mRNA into proteins or posttranslational modulation of 
enzyme activity could have higher impact on the cells lipid-storing capacity.  
 
3.6 LIPID CONTENT IN LIVER AND MUSCLE 
Lipid content was measured in both liver and the tibialis muscle. Note that the results show 
the content of the whole organ, not the concentration per weight unit. Liver weights were 
about the same for all groups, whereas muscle weights were highest in chow group and lowest 
in fructose group (see Fig 3.2, F and G).  
The amounts of total lipid in liver (Fig 3.12A) did not differ between groups. In contrast, 
triacylglycerol contents were significantly lower in glucose and fructose group compared to 
chow group (Fig 3.12B). Also sucrose group exhibits somewhat lower values, making it a 
trend that the fish oil groups have the lowest contents of triacylglycerol (TAG). The amounts 
of phospholipids were higher in the groups given fish oil, and the difference was significant 
for the sucrose and glucose groups compared to chow group (Fig 3.12C). Phospholipids are 
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primarily components of cellular membranes, and the higher levels of phospholipids in the 
liver of the fish oil groups merely indicate a higher number of cells of smaller size in these 
groups. This explain why the total lipid content was similar between groups, even though 
TAG content was reduced in the fish oil groups. Cholesterol contents were about the same for 
all groups (Fig 3.12D).  
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Figure 3.12: Lipid content in liver (A-D) and muscle (E-H). The amounts of total lipids (A and E), 
triacylglycerol (B and F), phospholipids (C and G) and cholesterol (D and H) were measured. Groups 
marked by different letters are significantly different. 
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Amounts of total lipid in the tibialis muscle were highest in the sucrose group, although the 
difference did not reach statistical significance (Fig 3.12E). Triacylglycerol contents were 
significantly reduced in glucose and fructose group, compared to chow group (Fig 3.12F), 
which is consistent with the results seen in hepatic triacylglycerol content (Fig 3.12B). 
Amounts of phospholipids in muscle are higher in the fish oil groups compared to chow group 
(Fig 3.12F). This is also consistent with the results of phospholipid content in liver (Fig 
3.12B). The phospholipid content in muscle is significantly higher for the fructose group 
compared to chow group (Fig 3.12G).  Cholesterol contents are somewhat higher in fish oil 
groups compared to chow group and the difference is significant for the fructose group (Fig 
3.12H).  
 
3.7 PLASMA PARAMETERS 
All plasma parameters were measured from fed mice. Plasma insulin levels were not expected 
to differ much in the fed state, and indeed the results were not significantly different (not 
shown). The results of the plasma glucose, glycerol, triglyceride, alanine transaminase, lactate 
dehydrogenase and D3 hydroxybutyrate are shown in figure 3.12.  
 
Figure 3.13: Plasma levels of glucose (A), glycerol (B), triglyceride (C), alanine transaminase (D), 
lactate dehydrogenase (E) and D3 hydroxybutyrate (F). Groups marked by different letters are 
significantly different. 
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Plasma glucose (Fig 3.13A) did not show any significant differences, as is expected in the fed 
state. In the fasted state, elevated plasma glucose is also a sign of Type 2 diabetes. Differences 
in plasma glycerol levels (Fig 3.13B) were not significantly different, but it indicates that the 
fructose group has the lowest levels.  
Elevated plasma triglyceride level is a sign of insulin resistance. Fructose group had the 
lowest levels of plasma triglyceride, significantly lower than chow group (Fig 3.13C). This is 
consistent with the chow group being the fattest and the fructose group being the leanest. 
Elevated levels of alanine transaminase (ALT) are a sign of liver damage. The differences did 
not reach significant differences, but it seems glucose and fructose group have lower values 
compared to chow and sucrose group (Fig 3.13D).  
Lactate dehydrogenase (LDH) is an enzyme which converts pyruvate into lactate to produce 
energy, without the expenditure of oxygen. Elevated level of LDH is a sign of tissue 
breakdown. No significant differences were reached, but the fructose group clearly has the 
highest levels (Fig 3.13E).  
D3 hydroxybutyrate is a ketone body which can be used as a source of energy when glucose is 
in short supply. There were no differences in the levels of D3 hydroxybutyrate between 
groups (Fig 3.13F). 
 
3.8 HISTOLOGY    
Histological examinations were done to visualize the morphologies of the adipose tissues. 
Unfortunately, the tissues did not survive the storage time while I was away during maternity 
leave. Histology was performed twice with the variations describes in Materials and methods, 
but all tissues had degraded. A section of the disrupted tissue can be seen in Appendix III. 
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4. RESULTS – STARCH GROUPS 
The aim of this study was to investigate whether the GI index of the food in combination with 
fish oil would affect the mice in any way.  
This study consists of two experimental groups in addition to the control group. One group 
was fed food containing the low GI starch amylose. The other group was fed food containing 
the high GI starch amylopectin. The control group ate standard mice chow and is the same 
control group used in the parallel study of sugars and fish oil. The diet composition is shown 
at page 40 of Materials and methods. The concept of the GI index is explained at page 16-17 
of the Introduction. A meal-tolerance test of low and high GI diets comparable to ours, 
performed on C57BL/6J mice, is illustrated in Appendix IV.  
The two experimental groups were pair-fed, so that all mice received the same amount of 
calories. They were also pair fed with the sugar groups in the parallel study, to make it 
possible to compare any of the five experimental diets. From now on the different diet groups 
in this study will be labeled chow, low GI and high GI. Any significant differences will be 
marked by different letters on the graphs. All genes measured were normalized to the 
housekeeping gene TBP. 
 
4.1 FOOD INTAKE, BODY WEIGHT DEVELOPMENT AND FEED EFFICENCY 
The mice were fed the experimental diets for 9 weeks. The chow group was given food ad 
libitum, whereas the other groups were restricted in their food intake. The chow feed 
contained lesser calories per gram than the other feeds, so these mice ate more food measured 
in grams than the other groups (not shown). The accumulated calories ingested, the weight 
gain and the energy efficiency is shown in Figure 4.1A-C. The body weight development is 
shown in figure 4.1D.  
The pair-fed experimental groups ate roughly the same amount of calories. The chow group 
ingested less calories compared to the low GI group (Fig 4.1A). After 9 weeks of feeding, the 
mice where weighed before termination. The total weight gain in grams is shown in figure 
4.1B. Mice on fish oil diets gained less weight than mice on chow diet, but the difference is 
statistically significant only for the low GI group. The energy efficiency is shown in figure 
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4.1C. Both groups on fish oil diets had to eat more calories to gain weight compared to the 
chow group, but the difference is only significant for the low GI group. There is clearly a 
difference between low and high GI diets in respect to weight gain and calorie efficiency, but 
the differences between the two groups are not large enough to reach significant levels.  
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Figure 4.1: Feed intake and body weight development of the C57BL/6J mice. Total calories ingested 
(A), total weight gain from start to end of the experiment (B), weight gain (g) per calorie ingested (C) 
and body weight development during the experiment. Groups marked by different letters are 
significantly different. 
The mice were weighed twice a week. The body weight development is shown in figure 4.1D. 
There was a drop in the weight development some days before termination due to changes in 
the mice’s environment, but it does not seem to have affected the end result. As seen from the 
graph, the low-calorie chow group who ate fewer calories, gained the most weight. The low 
GI diet group, who ate the most calories, ended up as the lightest group.  
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4.2 ORGAN WEIGHTS 
Figure 4.2A shows the end mean body weights of the groups. After termination, organ 
weights were recorded. We harvested the retroperitoneal adipose tissue (Fig 4.2B), 
epididymal adipose tissue (Fig 4.2C), inguinal adipose tissue (Fig 4.2D), intrascapular brown 
adipose tissue (Fig 4.2E), tibialis muscle (Fig 4.2F) and liver (Fig 4.2G). 
 
Figure 4.2: Total body weight (A), rWAT weight (B), eWAT weight (C), iWAT weight (D), iBAT weight 
(E), tibialis weight (F) and liver weight (G). All weights are displayed in grams. Groups marked by 
different letters are significantly different.  
In this experiment, total body weight was significantly lower for the low GI group compared 
to chow group (Fig 4.2A). This difference did not reach significant levels for the high GI 
group, nor in any of the groups who ate sugars (Fig 3.2A). Adipose tissues were continuously 
smaller in the low GI groups (Fig 4.2B-E). The subcutaneous fat depot inguinal WAT 
(iWAT) varied the most, low GI had significantly less iWAT compared to chow group, and 
high GI group had significantly more iWAT compared to chow group (Fig 4.2D). The 
difference in intrascapular brown adipose tissue (iBAT) was less protrudent, low GI group 
had significantly less iBAT compared to the chow group, but the difference was not 
significant compared to the high GI group (Fig 4.2E). Weight of the muscle (Fig 4.2F) and 
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liver (Fig 4.2G) organs did not show any significant differences, although the lighter mice in 
the low GI group had somewhat smaller tibialis muscles.  
 
4.3 HEPATIC GENE EXPRESSION 
The same genes were measured in the starch groups as in the sugar groups.  
Lipogenic gene expression 
The relative expression levels of lipogenic genes are shown in figure 4.3. We measured the 
relative expressions of Srebp1c, Acc1, Acc2, Scd1, Fas and Dgat. The function and regulation 
of these genes are described at page 21-25 of the Introduction.  
 
Figure 4.3: Relative expression levels of hepatic Srebp1c (A), Acc1 (B), Acc2 (C), Scd1 (D), Fas (E) 
and Dgat (F) mRNA. Groups marked by different letters are significantly different.  
The groups who were given fish oil showed a tendency towards lower expression levels of the 
lipogenic transcription factor Srebp1c compared to the chow group (Fig 4.3A), although the 
results were not significantly different. The chow group has significantly higher expression 
levels of the lipogenic enzymes Acc1, Acc2, Fas and Scd1 (Fig 4.3B-E), which are influenced 
by the SREBP-1c transcription factor. Both fish oil groups have a tendency towards lower 
expression levels of these genes, but the low GI group continuously has even lower 
expression rates compared to high GI group. The difference was biggest for the Scd1 
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expressions, where the low GI group had significantly reduced Scd1 levels compared to high 
GI group (Fig 4.3E). This shows that the type of carbohydrate ingested affects the ability of 
PUFAs in fish oil to decrease lipogenesis. Like in the parallel study of sugar diets, expression 
levels of Dgat did not vary between groups (Fig 4.3F).  
 
Genes increasing fatty acid breakdown 
The relative expression levels of the genes which increases fatty acid breakdown are shown in 
figure 4.4. We measured the expression levels of Pparα, Pparδ, Aco, Cpt1a, Cpt2 and 
Hmgcs2. The function and regulation of these genes are described at page 25-28 of the 
Introduction.  
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Figure 4.4: Relative expression levels of the genes Pparα (A), Pparδ (B), Cpt1a (C), Cpt2 (D), 
Hmgcs2 (E) and Aco (F) in liver. Groups marked by different letters are significantly different.  
There were no significant differences in the expressions of Pparα, Pparδ, Cpt1a or Hmgcs2 
(Fig 4.4 A, B, C and E). This is in correlation with the results from the parallel study of mice 
given different sugars in combination with fish oil (Fig 3.4). Cpt2-expressions were higher in 
the fish oil groups compared to the low-fat chow group, and the difference was significant for 
the low GI group (Fig 4.4D). Aco expression levels were also higher in fish oil groups, but 
here the difference was significant only for the high GI group (Fig 4.4F).  
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Gluconeogenesis 
The relative expression levels of genes involved in gluconeogenesis are shown in figure 4.5. 
We measured the expression levels of Pgc1α and Pck1. These genes are described at page 28 
of the Introduction. 
 
Figure 4.5: Relative expressions of the gluconeogenetic enzymes Pgc1α (A) and Pck1 (B) in liver. 
Groups marked by different letters are significantly different.  
Like in the study of the sugar diets, mice given fish oil had somewhat reduced expression 
levels of Pgc1α, although the difference did not reach statistical significance (Fig 4.5A and 
B). The fish oil groups did however have somewhat elevated levels of Pck1, but standard 
errors were high.  
 
Amino acid degradation 
The relative expression levels of genes involved in amino acid degradation are shown in 
figure 4.6. We measured to expressions of Agxt, Got, Gpt1 and Cps1. The enzyme products of 
these genes are described at page 29 of the Introduction.  
Like in the study of the sugar diets, only Agxt showed significant differences (Fig 4.6A). Agxt 
expression levels are reduced in both fish oil groups, but the difference is only significant for 
the low GI group. The expression levels of Got, Gpt1 and Cps1 also show a tendency towards 
lower values in the fish oil group, although the differences do not reach statistical significance 
(Fig 4.6 B-D).  
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Figure 4.6: The relative expressions of mRNA coding for hepatic enzymes involved in amino acid 
degradation. Agxt (A), Got (B), Gpt1 (C) and Cps1 (D) were measured. Groups marked by different 
letters are significantly different.  
 
Cyclic AMP signaling 
The relative expression levels of genes involved cyclic AMP (cAMP) signaling are shown in 
figure 4.7. We measured the expression levels of RIα, RIIβ, Crem and Pde4c. These genes are 
described at page 30-31 of the Introduction.  
As seen in the study of sugar diets, there were no significant differences in the RIα and RIIβ 
expression levels, although RIα seems to be somewhat reduced in the low GI diet group (Fig 
4.7A and B). The RIα: RIIβ ratios were also a little lower in the fish oil groups compared to 
chow group (Fig 4.7C). The levels of Crem were significantly reduced in the fish oil groups 
compared to the chow group (Fig 4.7D). The levels of Pde4c were not significantly different, 
although there was a slight reduction in the fish oil groups (Fig 4.7E). This trend was also 
seen in the fish oil groups from the sugar diet study (Fig 3.7E). 
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Figure 4.7: cAMP signaling. The relative expressions of RIα (A), RIIβ (B), Crem (D) and Pde4c (E). 
Figure 7C shows the RIα: RIIβ-ratio. Groups marked by different letters are significantly different.  
 
4.4 GENE EXPRESSIONS IN WHITE ADIPOSE TISSUE 
Expressions of genes involved in adipogenesis, inflammation and genes that give white 
adipocytes a brown-like phenotype were measured in white adipose tissue. The same genes 
were measured in this experiment as in the sugar diets experiment.  
Adipogenesis  
The relative expressions of Pparγ2, Srebp1c and Fas were measured in eWAT and iWAT 
(Fig 4.8). These genes are described at page 21-25 of the Introduction.  
As in the experiment with the sugar diets, differences in the levels of Pparγ2, Srebp1c and 
Fas did not reach significant differences (Fig 4.8A-F). The levels in eWAT were a bit higher 
in the fish oil groups, and the levels in iWAT were a bit lower in the fish oil groups. The same 
pattern for the iWAT expression levels of lipogenic genes are seen in the fish oil groups of the 
sugar study (Fig 3.8).  
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Figure 4.8: Relative expressions of adipogenic genes in white adipose tissue:  Pparγ2 (A and B), 
Srebp1c (C and D) and Fas (E and F). Measurements from epididymal fat to the left and inguinal fat to 
the right.  
 
Inflammation markers 
The expression levels of the inflammation markers Ccl2, Cd68, Emr1 and Serpine1 were 
measured in eWAT and iWAT. Results from Serpine1 are not shown due to high standard 
errors of the mean. These genes are described at page 31-34 of the Introduction. The results 
are shown in figure 4.9. 
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Figure 4.9: Relative expression levels of inflammatory genes in white adipose tissue:  Ccl2 (A and B), 
Cd68 (C and D) and Emr1 (E and F). Measurements from epididymal fat to the left and inguinal fat to 
the right. Groups marked by different letters are significantly different. 
Expression levels in eWAT showed no statistical significant differences (Fig 4.9 A, C and E). 
The low GI group had lower expressions of for Ccl2, Cd68 and Emr1 compared to the high 
GI group.  
The expressions of the inflammatory genes in iWAT were lower in the low GI group (Fig 4.9 
B, D and F), and the difference was significant for Ccl2 and Emr1, compared to the chow 
group (Fig 4.9 B and F).  
RESULTS – STARCH GROUPS 
81 
Brown-like phenotype of WAT 
We measured the expression levels of Pgc1α and Ucp1 in eWAT and iWAT. For reasons 
described at page 65, results from Ucp1 measurement are not shown, but the expression level 
of Pgc1α is found in figure 4.10. The function of PGC-1α in adipose tissue can be found at 
page 35 of the Introduction.  
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Figure 4.10: The relative expression levels of Pgc1α in epididymal (A) and inguinal (B) fat.  
The low GI group has significantly elevated expression levels of Pgc1α in visceral fat 
compared to the chow group (Fig 4.10A). Levels of Pgc1α in subcutaneous fat do not reach 
statistical significant differences, but the levels are somewhat reduced on both fish oil groups 
(Fig 4.10B). These results are consistent with the results found in the sugar diets study (Fig 
3.10).  
 
3.5 GENE EXPRESSION LEVELS IN BROWN ADIPOSE TISSUE 
In intrascapular brown adipose tissue (iBAT), Pgc1α, Dio2 and Ucp1 were measured to 
examine differences in adipocyte phenotypes. Unfortunately, for reasons described above, 
Ucp1 results are not shown. The expression levels of Cox2 were determined as a measurement 
of mitochondrial function. The expressions of the lipogenic genes Srebp1c and Rip140 were 
also measured in iBAT. The enzyme products of these genes are described at page 34-36 of 
the Introduction. The results are displayed in figure 4.11. 
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Figure 4.11: The expression levels of genes involved in adipocyte phenotype, mitochondrial function 
and lipogenesis in BAT. Pgc1α (A), Dio2 (B), Cox2 (C), Srebp1c (D) and Rip140 (E). Groups marked 
by different letters are significantly different. 
Fish oil groups showed a trend towards higher expression levels of the Bat-specific genes 
Pgc1α (Fig 3.11A) and Dio2 (Fig 3.11B) compared to the chow group. The difference was 
significant for Dio2 (Fig 3.11B). This might indicate that the fish oil groups had a higher 
capacity of turning fat into heat, which would explain why they are leaner while they still ate 
more calories than the chow group. Interestingly, the heavier high GI group had slightly 
higher levels of these genes compared to the low GI group. The fish oil groups did not, 
however, have higher levels of Cox2 compared to the chow group (Fig 4.11C). 
The expression levels of lipogenic genes are, as seen in the sugar diets study, less consistent. 
Both fish oil groups had significantly reduced levels of Srebp1c compared to chow group (Fig 
4.11D), but the expression levels of Rip140 were lower in the chow group. This is also 
consistent with the results found in the sugar diets study.  
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4.6 LIPID CONTENT IN LIVER AND MUSCLE 
Lipid content was measured in both liver and the tibialis muscle. Note that the results show 
the content of the whole organ, not the concentration per weight unit. Liver weights were 
about the same for all groups, whereas muscle weights were somewhat lower in the low GI 
group (see Fig 4.2, F and G).   
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Figure 4.12: Lipid content in liver (A-D) and muscle (E-H). The amounts of total lipids (A and E), 
triacylglycerol (B and F), phospholipids (C and G) and cholesterol (D and H) were measured. Groups 
marked by different letters are significantly different. 
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The amounts of total lipid in liver (Fig 4.12A) did not differ between groups. In contrast, liver 
triacylglycerol contents were lower in both fish oil groups compared to chow group, and the 
difference reach statistical significance for the low GI group (Fig 4.12B). This trend was also 
seen in the sugar diets study (Fig 3.12B). The amounts of phospholipids were higher in the 
fish oil groups compared to the low-fat chow group, and the difference was significant for the 
low GI group (Fig 4.12C). Cholesterol contents were somewhat higher in the low GI group, 
but the difference was not statistically significant (Fig 4.12D).  
Lipid contents in the tibialis muscle were consistently higher in the high GI group (Fig 4.12 
E-H). Total lipid contents were higher in both fish oil groups compared to chow group, and 
the difference reached statistical significance for the high GI group (Fig 4.12E). 
Triacylglycerol contents were somewhat lower in the low GI group, but the difference was not 
significant (Fig 4.12F). Amounts of phospholipids in muscle did not show high variations 
between groups, but the low GI group had somewhat lower phospholipid contents compared 
to high GI group (Fig 4.12G). Cholesterol contents followed the same pattern (Fig 4.12H).  
 
4.7 PLASMA PARAMETERS 
All plasma parameters were measured from fed mice. Plasma insulin levels were not expected 
to differ much in the fed state, and indeed the results were not significantly different (not 
shown). The results of the plasma glucose, glycerol, triglyceride, alanine transaminase (ALT), 
lactate dehydrogenase (LDH) and D3 hydroxybutyrate are shown in figure 4.13.  
Plasma glucose did not show any significant differences, as is expected in the fed state, but 
the low GI group has slightly reduced levels compared to the other groups (Fig 4.13A). 
Plasma glycerol was lower in the fish oil groups compared to the chow group, but the 
difference did not reach statistical significance (Fig 4.13B). Plasma triglyceride levels are 
significantly reduced in the fish oil groups compared to the chow group (Fig 4.13C). The 
values of plasma ALT varied within groups, but it seems that the low GI group has the lower 
values compared to the other groups (Fig 4.13D). High levels of ALT may be a symptom of 
liver failure. Differences in plasma LDH did not vary between groups (Fig 4.13E). The levels 
of the ketone body D3 hydroxybutyrate did not reach significant differences, but was slightly 
elevated in the low GI group (Fig 4.13F).  
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Figure 4.13: Plasma levels of glucose (A), glycerol (B), triglyceride (C), alanine transaminase (D), 
lactate dehydrogenase (E) and D3 hydroxybutyrate (F). Groups marked by different letters are 
significantly different. 
 
4.8 HISTOLOGY 
Histological examinations were done to visualize the morphologies of the adipose tissues. 
Unfortunately, the tissues did not survive the storage while I was away during maternity 
leave. Histology was performed twice, but all tissues had degraded.  
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5. DISCUSSION 
Previous studies have demonstrated the anti-obesogenic effects of fish oil in obesity-
promoting diets (Arai et al 2009, Belzung et al 1993, Flachs et al 2005). The present studies 
were performed to elucidate whether the anti-obesogenic effect of fish oil is influenced by 
types of carbohydrates in the background diet. The experimental diets contained the same 
amounts fat, protein and carbohydrates. The types of fat and protein were equal, whereas the 
type of carbohydrate varied. The animals in the experimental groups were all pair-fed. We 
wanted to investigate potential differences in body weight, adipose tissue weights, 
lipogenesis, fatty acid breakdown, gluconeogenesis, amino acid degradation, brown-like 
phenotypes in adipose tissues, inflammation, accumulation of fatty acids in liver, muscle and 
plasma, and plasma other parameters.  
 
5.1 ANIMAL MODEL AND DIETS 
36 male C57BL/6J mice were given 6 different diets. The C57BL/6J (black six) mouse model 
was chosen because it is widely used in obesity studies, which makes it possible to compare 
results with previously performed studies. The black six mice easily develop diet-induced 
obesity and metabolic traits seen in obese humans over a relatively short period of time. It 
also lacks the ability to induce thermogenesis when exposed to high-caloric diets, a trait that 
is seen in obesity-resistant mice (Collins et al 2004).  
One of the diets was standard chow diet, high in carbohydrates and low in fat. The other diets 
were high fat diets containing primarily fish oil, but also a small of amount soy bean oil, 
which provides n-6 fatty acids, also required for growth. The experimental diets contained 
high sucrose, high glucose, high fructose, high amylose or high amylopectin, as listed in table 
2.1, page 40. 
 
5.2 BODY WEIGHT DEVELOPMENT AND FEED EFFICIENCY 
Of all the groups, the group given standard chow diet gained the most weight, despite the fact 
that they did not eat more calories than other groups. The amount of energy is lower in the 
low fat feed than in the experimental diets, but as the chow fed mice consumed more feed, the 
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energy intake was comparable. It should be noted that the amount of eWAT in the chow 
group, which was more than average 1g, indicates that the low fat fed mice were obese. This 
shows that fish oil to some extent protects against obesity, regardless of the type of 
carbohydrate ingested. Of the different fish oil groups, the mice given glucose as their main 
carbohydrate gained the most weight, closely followed by the sucrose group, whereas the 
fructose group remained relatively lean, indicating that the obesogenic effect of sucrose stems 
from the glucose molecule. It is to be noted that the mean weight gain of the glucose and 
sucrose groups were very close (4.7 g and 4.6 g). When digested, sucrose is split into one 
molecule of glucose and one molecule of fructose, so these results clearly show that while 
fructose in this study does not have an obesogenic effect, it doesn’t protect against obesity 
either. Mice receiving the high GI starch became as obese as the sucrose fed mice, whereas 
the low GI group remained relatively lean.  
 
5.3 ADIPOSE TISSUE DEVELOPMENT 
As previously mentioned, visceral adipose tissue is regarded as more unhealthy and increases 
the risk of developing Type 2 diabetes and metabolic syndrome, compared to subcutaneous 
adipose depots. The sucrose group developed the most visceral fat mass (eWAT and rWAT 
combined) of all groups, closely followed by high GI group (Fig 3.2A+B and 4.2 A+B). The 
percentage of visceral fat mass of total body weight is illustrated in figure 5.1. The chow 
mice, although heavier, had less visceral adipose tissue mass compared to mice given sucrose 
and high GI starch. This might indicate that even though the chow mice were bigger and most 
likely were fatter, they probably had a more healthy body composition of more subcutaneous 
fat mass compared to visceral fat mass. On the other end of the scale, the fructose and low GI 
fed mice developed the least adipose tissue mass and also had smaller visceral adipose depots 
compared to total body weight.  
The distribution of subcutaneous fat is not illustrated, since we only dissected one depot of 
this fat and this might not be representative for the total subcutaneous fat mass. As mentioned 
in the Introduction, subcutaneous fat is distributed under the skin, all over the body. For future 
studies, I suggest an in vivo MRI scan of the animals to visualize the total body fat content.  
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Figure 5.1: Visceral fat (eWAT + rWAT combined) weight of total body weight, in percent. The 
different amounts and different distributions of body fat clearly show that the carbohydrates in the diet 
affect the anti-obesogenic effect of fish oil.  
 
5.4 ENERGY EFFICIENCY  
Both fructose and low GI group had significantly reduced energy efficiencies compared to the 
chow group, despite the fact that the fructose group ate the same amount of calories and the 
low GI group even ate more. The mice were kept in equal cages under equal conditions, but it 
is theoretically possible that the fructose and low GI mice were more physically active 
compared to other groups. Any differences in activity levels were not detectable by normal 
observation during the feeding trial. It is more likely that the differences in energy efficiency 
are in fact due to the carbohydrate components of the diets. This is also supported by the 
differences found in expressions of genes involved in metabolism and brown-like phenotypes 
of adipocytes. Other studies have also found differences in feed efficiency of pair-fed mice 
(Madsen et al 2008). 
 
5.5 GENE EXPRESSION LEVELS IN LIVER 
PUFAs are demonstrated to reduce hepatic levels of the lipogenic transcription factor Srebp1c 
(Xu et al 2001). Liver Srebp1c was not downregulated in our fish oil groups, but the fish oil 
groups seemed to be protected against elevated levels of the lipogenic genes Acc1, Acc2, Fas 
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and Scd1 (Figs 3.3 and 4.3). This may be due to the fact that the SREBP-1c enzyme has to be 
activated before functioning as a transcription factor (Horton et al 2002). High level of 
Srebp1c mRNA is not a guarantee for high levels of active SREBP-1c enzyme, since the 
enzyme is regulated by posttranslational modifications. As seen from the expression levels of 
Acc1, Acc2, Fas and Scd1, SREBP-1c is probably more active in the chow group, but not in 
the fish oil groups. PUFAs found in fish oil are demonstrated to disrupt the inactive precursor 
proteins of SREBP-1c before they reach the nucleus (Yahagi et al 1999). This reduces the 
expressions of lipogenic genes in the liver (Osborne 2000).  
The expression levels of the genes involved in fatty acid breakdown could not explain why 
the fish oil mice were leaner compared to the mice who ate chow feed. The expression levels 
of Cpt2 were upregulated in the fish oil groups (Figs 3.4 and 4.4). This is probably not of 
physiological relevance, because CPT2 is not a rate-limiting enzyme (Eaton 2002). The rest of 
the genes coding for mitochondrial enzymes, Pparα, Pparδ, Cpt1a and Hmgcs2, did not show 
any significant differences. PPARα and PPARδ are transcription factors which have to be 
activated posttranslationally (Chawla et al 2001), so the slight reduction of these genes seen in 
some of the fish oil groups is alone not enough to support a theory of increased fatty acid 
breakdown. On the other hand, the mRNA levels of the peroxisomal enzyme ACO were 
higher in all fish oil groups compared to the chow group. This might not be a anti-obesity 
effect of the fish oil, since this enzyme specifically oxidized long-chained PUFAs, as found in 
fish oil (Duplus and Forest 2002). Aco levels are higher in the sucrose, glucose and high GI 
groups compared to the fructose and low GI groups. This is probably due to the size of the 
adipose tissue mass, and not caused by a beneficial effect of sucrose, glucose and high GI 
starch. The large adipose tissue mass found in these groups means that there are more long-
chained fatty acids available for oxidation, and therefore Aco is upregulated. 
Hyperglycemia is a symptom of insulin resistance and development of Type 2 diabetes (Hajer 
et al 2008). The hyperglycemia seen in obese patients is partly due to increased hepatic 
gluconeogenesis. Obese mice are previously demonstrated to have elevated levels of hepatic 
Pgc1α and Pck1, which are involved in gluconeogenesis (Yoon et al 2001). All the fish oil 
groups did have reduced expressions of Pgc1α, even though three of the groups were obese 
(Figs 3.5 and 4.5). PGC-1α activity is regulated by phosphorylation and deacetylations (Lin et 
al 2005), so although the result is interesting, we cannot claim that our fish oil mice are 
protected from increased gluconeogenesis without supporting findings from Pck1 expressions, 
which was not reduced in the fish oil groups.  
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Upregulation of Agxt, Got, Gpt1 and Cps1, which are involved in amino acid degradation, is 
not a good thing for the obese mouse. All our mice ate the same amount of proteins, so high 
amino acid degradation could imply that the mice have increased rates of gluconeogenesis. 
All our fish oil groups showed a tendency towards reduced expressions of Agxt, Got, Gpt1 
and Cps1 compared to the chow group (Figs 3.6 and 4.6). This might indicate that the mice 
given fish oil were protected against amino acid-derived hyperglycemia.  
Of genes involved in cAMP signaling, only Crem showed significant differences (Figs 3.7 
and 4.7). Crem was significantly reduced in all the fish oil groups, save the sucrose group 
where the difference did not reach significant levels. CREM is a transcription factor that can 
be translated into both an activator or a repressor of CRE-genes (Inada et al 1999), making the 
mRNA levels of this gene impossible to interpret. The results clearly show that this gene is 
affected by the fish oil, and I suggest that the activity level of this protein should be measured 
in future studies. 
 
5.6 GENE EXPRESSION IN WHITE ADIPOSE TISSUE 
The transcription factors Pparγ2 and Srebp1c, involved in adipogenesis, were somewhat 
downregulated in the subcutaneous fat pad of fish oil mice (Figs 3.8 and 4.8). The Fas gene 
was even more profoundly downregulated. This was not seen in the visceral fat pad, where 
these genes were expressed at comparable or higher levels compared to the chow group. This 
may indicate that the PUFAs in fish oil protect these mice against adipogenesis in 
subcutaneous, but not visceral fat. Considering the fact that the fructose group has higher 
levels of lipogenic genes compared to other fish oil groups, it is likely that the regulations of 
these genes are affected by the diet, not by the degree of obesity.  
The n-3 fatty acids EPA and DHA are associated with reduced levels of inflammatory 
macrophages, which reduced the burden of inflammation (Oh et al 2010). The inflammation 
markers in visceral fat were upregulated in the sucrose group compared to all other groups. Of 
the sugar groups, fructose continuously had the lowest expression levels of inflammatory 
markers, but the difference was not significant compared to the chow group (Fig 3.9). Of the 
starch groups, the low GI group had somewhat lower expression levels compared to the high 
GI group (Fig 4.9). When comparing the sucrose group and the high GI group, the 
inflammation markers are higher in the sugar group (not shown). In the subcutaneous fat pad, 
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the sugar groups showed no consistent trend towards higher or lower levels of inflammation 
markers compared to the chow group. The starch groups, on the other hand, had lower levels 
of Ccl2 and Emr1. The levels were lower in the low GI group compared to the high GI group. 
To sum it up, inflammation is probably lower in the fructose and low GI group, compared to 
the chow group. PUFAs did not protect against inflammation in sugar, glucose and high GI 
group. We cannot at this point say whether this is related to the types of carbohydrates 
ingested or the level of obesity of the animals.  
Pgc1α is upregulated in epididymal fat of all fish oil groups compared to the chow group, but 
it is downregulated in the inguinal fat. Since the fish oil groups were lighter compared to the 
chow group, the upregulation in the visceral epididymal fat pad is probably of physiological 
importance. One could postulate that the upregulation of Pgc1α in visceral adipose tissue may 
have positive health effects, since Pgc1α increases β-oxidation and heat production (Lin et al 
2005). Increasing fatty acid breakdown in the epididymal fat pad might limit the size of this 
unhealthy tissue. In consistency with this theory, the chow group had the highest percentage 
of visceral fat depots compared to total WAT (not shown).  
 
5.7 GENE EXPRESSION IN BROWN ADIPOSE TISSUE 
PGC-1α is a transcriptional coactivator for Ucp1 (Lin et al 2005), and Dio2 prolongs the 
longevity of the UCP-1 protein (Bianco et al 2002). Increased expressions of these genes in 
brown adipose tissue are indicators of increased capacity of burning fat. Dio2 was indeed 
upregulated in all fish oil groups, compared to the chow group. The levels of Pgc1α was only 
elevated in the fructose group, but as mentioned earlier, PGC-1α activity is modified 
posttranslationally, meaning that Pgc1α mRNA levels are not always a good measurement of 
PGC-1α enzyme activity.  
The lipogenic transcription factor Srebp1c is downregulated in brown adipose tissue of all fish 
oil groups, excluding the glucose group. This is in consistence with earlier studies (Kim et al 
1999). Also, Rip140, which is a repressor of fatty acid oxidation, is upregulated in the fish oil 
groups.  
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5.8 TRIGLYCERIDE CONTENT IN LIVER, MUSCLE AND PLASMA 
Elevated levels of triglycerides (TGs) are a sign of insulin resistance and the possible 
development of hepatic steatosis. It is caused by increased release of fatty acids from the 
adipose tissues, which is seen in obese patients (Ferre and Foufelle 2010, Hajer et al 2008). 
The total hepatic lipid content did not differ between groups, but the TG contents were 
reduced in all fish oil groups. The TG contents of the tibialis muscle were reduced in glucose, 
fructose and low GI group, but raised in the sucrose and high GI group. In plasma, TG was 
reduced in all fish oil groups. This means that fish oil protects from TG accumulation 
regardless of the carbohydrate ingested, but more so when the mice eats low GI food.  
The higher levels of phospholipids seen in the fish oil groups are not of pathological 
relevance. Phospholipids are primarily found in cellular membranes, and a high level of these 
fatty acids merely indicates that the livers of the fish oil groups contains an increased number 
of smaller cells compared to the chow group.  
The combined results from the liver, muscle and plasma analysis showed that none of the 
mice suffered from liver damage. 
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6. CONCLUSIONS 
Fish oil to some extent protects the mice against weight gain, regardless of the type of 
carbohydrate in the diet. However, these studies clearly show that when administered with 
sucrose, glucose or high GI carbohydrates, fish oil does not protect against obesity. These 
mice grew less obese compared to the chow group, but they were still obese. This is of great 
concern, given that consumption of these carbohydrates remain high, even though WHO have 
recommended to decrease consumption of sugar (WHO 2011) and stated that populations 
with high sugar intake are at risk of developing obesity and other chronic diseases (WHO 
2003). 
The fructose and low GI carbohydrate fed mice remained relatively lean during the trial. The 
mice fed fructose demonstrate that fructose is not obesogenic, but the weight gain of the 
sucrose group clearly shows that the fructose moiety of the sucrose molecule does not protect 
against obesity either. Also, this diet is not suitable for human consumption. The amount of 
fructose added to the diet given is not comparable to the amount of fructose found in human 
diets. Fructose ingested from fruit and honey is accompanied by approximately the same 
amounts of glucose (Tappy and Le 2010), making it impossible to follow the diet given to the 
fructose group, unless one eats copious amounts of commercially fabricated fructose sugar. 
That might not be a good idea, since the health benefits from eating fructose are controversial. 
Although mice stay lean on a fructose diet, rats fed fructose quickly develop insulin resistance 
and become obese (Hwang et al 1987, Tran et al 2009). In humans, studies have linked 
fructose to dyslipidemia (Le et al 2009), raise fasting TG and LDL levels (Schaefer et al 
2009), decreased insulin sensitivity and increased visceral adiposity (Stanhope et al 2009). 
This might indicate that the fructose metabolism of humans is more similar to the fructose 
metabolism of rats, not mice. There are, however, no evidence indicating that eating fructose 
in moderate amounts in the form of fruits and honey is unsafe (Tappy and Le 2010).  
The lower obesogenic effect of fructose is probably because fructose does not raise insulin 
levels like glucose does. If one wishes to obtain the same weight responses as seen in the 
fructose group, it would be more sensible to try the low carbohydrate diet, which has a less 
dramatic impact on blood insulin and glucose levels compared to high GI carbohydrates 
(Pawlak et al 2004). A glucose meal-tolerance test of low and high GI carbohydrates given to 
C57BL/6 mice is illustrated in Appendix IV.  
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In this study we saw that eating high GI carbohydrates like sucrose, glucose and amylopectin 
to some extent disrupts the ameliorating effect of fish oil on the development of obesity. This 
means that one cannot rely on omega-3 supplements for weight management. Taking omega-3 
supplements and eating fish are good dietary habits in many respects, but it does not 
legitimize binging in high GI foods. The good news is that our low GI group exhibited far 
better responses compared to the high GI carbohydrate groups. The low GI diet of our study is 
not free of high GI components. As listed in table 2.1, page 40, it also contains some sucrose 
and amylopectin. This means that one does not have to follow an ascetic diet to benefit from 
the anti-obesogenic effects of fish oil, small improvements are likely to be seen by moderate 
dietary improvements.  
For future studies, it would be interesting to investigate the effects of a diet high in fish oil 
and low GI carbohydrate on humans. To my knowledge, there are to date no studies linking 
low GI diets to obesity or any health problems in humans, and there are several studies linking 
fish oil to positive health effects. A recent study also indicates that the amino acids present in 
fish can reduce adipose tissue mass (Liaset et al 2009). I suggest an intervention study with a 
diet rich in fish, vegetables and whole grains, including omega-3 supplements, where the 
patients register intake of sweets, cakes, potato chips and soda beverages. After the study, e.g. 
12 months, changes in adipose tissue mass would be recorded and compared to the amount of 
high GI carbohydrates and total calories ingested.  
This diet rich in fish and vegetables would also be applauded be many parents worldwide, 
who are struggling to encourage their children to finish their dinners. 
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APPENDIX I 
 
Table I.1: Chemicals and reagents used in RNA extraction 
Product Vendor 
Trizol Invitrogen art.no. 15596-026, USA 
Chloroform Merck, Germany 
Isopropanol (2-propanol) Arcus kjemi, Norway 
Ethanol Arcus kjemi, Norway 
DEPC Sigma art. No. F32490, USA 
RNase free ddH2O MilliQ Gradient, Lab-tec, Norway 
DNA free kit Ambion art.no. 1906, USA 
 
 
Table I.2: Chemicals and reagents used in RNA quality Bioanalyzer 
Product Vendor 
RNA 6000 Nano LabChip kit Agilent Technologies art.nr 5065-4476, USA 
RNA 6000 Ladder Ambion art.nr 7152, USA 
RNase free ddH2O  MilliQ Gradient, Lab-tec, Norway 
 
 
Table I.3: Chemicals and reagents used in RT-reaction 
Product Vendor 
TaqMan RT buffer 10X 
Applied Biosystems art.no N808 0234,  
TaqMan® Reverse Transcription 
Reagents, USA 
25 mM Magnesium Chlorid 
10 mM deoxyNTPs 
50 μM Oligo dT 16 primer 
RNase inhibitor (20 U/μl) 
Multiscribe reverse transcriptase (50 U/μl) 
RNase free ddH2O MilliQ Gradient, Lab-tec, Norway 
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Table I.4: Chemicals and reagents used in quantitative real-time PCR 
Product Vendor 
SYBR GREEN Master Roche, Norway 
Primer  Invitrogen Ltd, UK 
RNase free ddH2O MilliQ Gradient, Lab-tec, Norway 
 
Table I.5: Chemicals and reagents used in histology 
Product Vendor 
4% formaldehyde Merck art.no 1.04003.1000, Germany 
NaH2PO4 x H2O Merck art.no 1.06346.0500, Germany 
NaHPO4 x 2H2O Merck art.no 1.06580.0500, Germany 
Ethanol 100% Arcus kjemi, Norway 
RNase free ddH2O MilliQ Gradient, Lab-tec, Norway 
Methanol Merck art.no 1.06018.2500, Germany 
Xylene Prolabo, VWR, art.no 28973.328, USA 
Haematoxylin Chemi-teknik AS, Norway 
Eosin Y Chemi-teknik AS, Norway 
Entellan, rapid mounting medium for microscopy  
 
Merck art.no 1.07960.0500, Germany 
 
Table I.6: Chemicals and reagents in Insulin Mouse Ultrasensitive ELISA kit, 96 wells 
Product Vendor 
Insulin Mouse Ultrasensitive ELISA kit: DRG Instruments, GmbH, Germany 
Standard 0 Lot no 17609 
Standard 1 (0.175 μg/l) Lot no 17599 
Standard 2 (0.45 μg/l) Lot no 17600 
Standard 3 (1.0 μg/l) Lot no 17601 
Standard 4 (2.5 μg/l) Lot no 17602 
Standard 5 (6.5 μg/l) Lot no 17603 
Coated plate Lot no 15771 
Enzyme conjugate 11X Lot no 15878 
Enzyme Conjugate Buffer Lot no 17606 
Wash Buffer 21 X Lot no 17557 
TMB Substrate Solution Lot no 15873 
Stop Solution 0.5 M H2SO4 Lot no 17561 
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APPENDIX II 
Table II.1: Primer sequences used in quantitative real-time PCR. Obtained from Invitrogen Ltd, UK.  
Housekeeping genes 
TBP 5’→ 3’ ACCCTTCACCAATGACTCCTATG 
3’→ 5’ ATGATGACTGCAGCAAATCGC 
Calnexin 5’→ 3’ GCAGCGACCTATGATTGACAACC 
3’→ 5’ GCTCCAAACCAATAGCACTGAAAGG 
β-actin 5’→ 3’ ATGGGTCAGAAGGACTCCTACG 
3’→ 5’ AGTGGTACGACCAGAGGCATAC 
Tested genes 
Srebp1c 5’→ 3’ GGA GCC ATG GAT TGC ACA TT 
3’→ 5’ GCT TCC AGA GAG GAG GCC AG 
Acc1 5’→ 3’ TGCTGCCCCATCCCCGGG 
3’→ 5’ TCGAACTCTCACTGACACG 
Acc2 5’→ 3’ TTC CAG ATG CTA ATG GGT TG 
3’→ 5’ GCA GGT CCA GTT TCT TGT GTT 
Scd1 5’→ 3’ GATGTTCCAGAGGAGGTACTACAAGC 
3’→ 5’ ATGAAGCACATCAGCAGGAGG  
Fas 5’→ 3’ CTTCGCCAACTCTACCATGG 
3’→ 5’ TTCCACACCCATGAGCGAGT 
Dgat 5’→ 3’ GGTGCCATCGTCTGCAAGA  
3’→ 5’ CCACCAGGATGCCATACTTGA  
Pparα  5’→ 3’ CGTTTGTGGCTGGTCAAGTT 
3’→ 5’ AGAGAGGACAGATGGGGCTC 
Pparδ 5’→ 3’ CAG AAG TGC CTG GCA CTC G 
3’→ 5’ TCC GTC CAA AGC GGA TAG C 
Aco 5’→ 3’ GGGTCATGGAACTCATCTTCGA 
3’→ 5’ GAATGAACTCTTGGGTCTTGGG 
Cpt1a 5’→ 3’ ACAAATTATGTGAGTGACTGG 
3’→ 5’ GATCCCAGAAGACGAATAGG 
Cpt2 5’→ 3’ AGCCTGCCCAGGCTGCC 
3’→ 5’ AAACCAGGGGCCCTGAGATG 
Hmgcs2 5’→ 3’ AGCCCAGCAGAGGTTTTCTACAA 
3’→ 5’ CATACGGGTCTGGCCCAAG 
Agxt 5’→ 3’ AAAAAGAGATGCTTCAGATCATGGA 
3’→ 5’ CACATACTGGATGCCTTGCTTG 
Got 5’→ 3’ TTTGTGTCTGAAGGCTTCGAGC 
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3’→ 5’ TCTCATTGTAGAGCCCGAAGTTCT 
Gpt1 5’→ 3’ AGGTCCTGGCCCTCTGTGTC 
3’→ 5’ CCTTCTCTTGGCATCCTCTGG 
Cps1 5’→ 3’ AGGATGTCAAGGTGTTTGGCA 
3’→ 5’ CTCGCTTAACTAGCAGGCGG 
Pgc1α  5’→ 3’ CATTTGATGCACTGACAGATGGA 
3’→ 5’ CCGTCAGGCATGGAGGAA 
Pck1 (Pepck) 5’→ 3’ CCACACCATTGCAATTATGC 
3’→ 5’ CATATTTCTTCAGCTTGCGG 
RIα 5’→ 3’ CCT ACG TTA GAA AGG TTA TTC C 
3’→ 5’ TAT CCC CTT CAT CAC CTT GC 
RIIβ 5’→ 3’ GCG TGC CTC GGT CTG TGC 
3’→ 5’ GGA CAT CTG CTC TGG ATC C 
Crem 5’→ 3’ AAGTCACATGGCTGCTGCC 
3’→ 5’ GCTCGGATCTGGTAAGTTGGC 
Pde4c 5’→ 3’ GGAGACACTGCAGACTCGTCG 
3’→ 5’ CATGCGCTTGAACTTGTTGG 
Pparγ2 5’→ 3’ ACAGCAAATCTCTGTTTTATGC 
3’→ 5’ TGCTGGAGAAATCAACTGTGG 
Ccl2 (Mcp1) 5’→ 3’ GTGTTGGCTCAGCCAGATGC 
3’→ 5’ GCTTGGTGACAAAAACTA 
Serpine1 (Pai1) 5’→ 3’ AGCGGGACCTAGAGCTGGTC 
3’→ 5’ CCAGTAAGTCATTGATCATACCTTTGGT 
Cd68 5’→ 3’ CTTCCCACAGGCAGCACAG 
3’→ 5’ AATGATGAGAGGCAGCAAGAGG 
Emr1 (F4/80) 5’→ 3’ CTTTGGCTATGGGCTCTCAGTC 
3’→ 5’ GCAAGGAGGACAGAGTTTATCGTG 
Dio2  5’→ 3’ GCC CAG CAA ATG TAG AC 
3’→ 5’ TGG CAA TAA GGA GCT AGA A 
Cox2 5’→ 3’ GACTGGGCCATGGAGTGG 
3’→ 5’ CACCTCTCCACCAATGACC 
Ucp1 5’→ 3’ AGCCGGCTTAATGACTGGAG 
3’→ 5’ TCTGTAGGCTGCCCAATGAAC 
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APPENDIX III 
 
Result of the histological procedures: 
 
Figure A: Disrupted adipose tissue. The depressing result of a lengthy histological method performed 
twice. 
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APPENDIX IV 
 
MTT-test of high and low GI starch: 
 
 
Figure B: The result of a meal-tolerance-test (MTT), performed on C57BL/6 mice. The diet contained 
high fat and the same amount of carbohydrates. The high GI group received Amioca (amylopectin), 
the low GI group received Hi-Maize (high in amylose). Adapted from (Coate and Huggins 2010)
  
 
 
